Drug, bio-affecting and body treating compositions inventions 10/07

20070248557 - Mild leave-on composition: The present invention relates to a leave on companion animal composition having a composition having a Total Lather Volume of from about 300 ml to about 700 ml, IL1α of from about 0 pg/ml to about 7000 pg/ml, and Friction Coefficient of from about 1.2 to about 2.0.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248561 - Water-soluble polymers and their use in cosmetic and pharmaceutical preparations: e

20070248564 - Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia: This invention relates to a stable, sorbitol free suspension formulation of sodium polystyrene sulfonate.... Agent: Pearne & Gordon LLP

20070248567 - Protein crosslinkers, crosslinking methods and applications thereof: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.... Agent: Dardi & Associates, PLLC

20070248534 - Auger effect-based cancer therapy method: A method for the treatment of a tumor, comprising administering to a subject a therapeutically effective amount of a complex of a heavy element with a polydentate, pyrrole-containing macrocyclic ligand substituted with charged chemical groups, wherein said complex is capable of bringing said heavy element into close proximity to the... Agent: Nixon & Vanderhye, PC

20070248533 - Stabilized and lyophilized radiopharmaceutical agents for destroying tumors: A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal... Agent: Brooke Schumm Iii

20070248539 - Agrm2 antigen: The antigen recognized by the antibody produced by a deposited cell line (ATCC accession no. PTA 5411) has been shown to be a fragment of vimentin. This vimentin fragment will be useful in therapy of and screening for cell proliferative disorders such as cancer.... Agent: Wilson Sonsini Goodrich & Rosati

20070248537 - Compositions and methods for cellular imaging and therapy: The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N4 compounds and derivatives.... Agent: Fulbright & Jaworski L.L.P.

20070248538 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic... Agent: Mchale & Slavin, P.A.

20070248535 - Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity: The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies. The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and... Agent: Wilmerhale/columbia University

20070248536 - Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography: The present invention relates to conjugates containing a covalent linkage between one or more polypeptide molecules based on gamma-crystallin or ubiquitin and one or more functional components. Furthermore, the present invention relates to a method for the preparation of such a conjugate as well as to the use of the... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070248540 - Biochemical methods for measuring metabolic fitness of tissues or whole organisms: The present invention relates to biochemical methods for assessing metabolic fitness and/or aerobic demands of a living system. Specifically, the rate of synthesis and turnover of the molecular components of mitochondrial mass are used to determine the aerobic capacity and/or aerobic demand of tissues or living organisms. The direct measurement... Agent: Morrison & Foerster LLP

20070248543 - Chicken deoxycytidine and deoxyadenosine kinase enzymes and their use: The application relates to the field of suicide gene therapy using expression vectors encoding a deoxynucleotide kinase capable of converting prodrugs into cytotoxic drugs. In particular, Chicken deoxycytidine kinase and eukaryotic deoxyadenosine kinase polypeptides and nucleotides encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are... Agent: Birch Stewart Kolasch & Birch

20070248542 - Devices and methods for individualized detection of nutrient imbalance via olfactory system: A method of detecting an imbalance of nutrients in an individual is disclosed. The method comprising administration of a smell test, wherein the smell test comprises one or more support members and one or more nutrients that are aroma-intensified and incorporated into one or more support members, the method further... Agent: Law Offices Of Khalilian Sira, LLC

20070248541 - Liposome: According to the present invention, a liposome encapsulating a water-soluble substance in an internal cavity of the liposome and having a liposome particle size of 300 nm or less can be easily prepared.... Agent: Leydig Voit & Mayer, Ltd

20070248544 - Mullerian inhibiting substance levels and ovarian response: Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and serve as prognostic indicators for the female response... Agent: University Of Medicine And Dentistry Of New Jersey Office Of Patents And Licensing

20070248545 - Use of the receptor gpr86: We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a GPR86 associated disease, in particular inflammatory disease or pain, the method comprising determining whether a candidate molecule is an agonist or antagonist of GPR86 polypeptide, in which the GPR86 polypeptide comprises the amino... Agent: Frommer Lawrence & Haug

20070248547 - Cascade macromolecular contrast agents for medical imaging: The present invention provides macromolecular contrast media for diagnostic imaging modalities.... Agent: Morgan, Lewis & Bockius, LLP

20070248546 - Clinical algorithm for excluding patients identified in virtual imaging: Aspects of the invention relate to clinical triage protocols for screening a patient population using virtual imaging techniques, for example, virtual colonoscopy. Methods for increasing the specificity of a virtual imaging procedure are provided. In aspects of the invention, colonic effluents are analyzed using one or more molecular detection assays.... Agent: Wolf Greenfield & Sacks, P.C.

20070248548 - Stable hydroalcoholic oral spray formulations and methods: Stable formulations of an active pharmaceutical agent suitable for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration of active pharmaceutical agent formulations are provided. Preferred embodiments of the invention provide formulations comprising an active pharmaceutical agent, a solvent, a buffer, and a... Agent: Dickstein Shapiro LLP

20070248549 - Water-soluble pharmaceutical compositions of hops resins: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions... Agent: Thorpe North & Western, LLP.

20070248550 - Cosmetic emulsions containing uncoated silicone elastomers and non silicone treated pigments: Disclosed are cosmetic compositions in the form of an emulsion that contain an uncoated silicone elastomer, a solvent for the elastomer, a non-silicone treated pigment and an emulsifier, methods of making the compositions, and methods of applying the compositions to a keratinous substrate or tissue.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070248553 - Consumer noticeable improvement in wetness protection: Antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (c) from about 10% to about 99% by weight of the composition, of an... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248552 - Consumer noticeable improvement in wetness protection using solid antiperspirant compositions: Anhydrous, solid antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (c) from about 10% to about 99% by weight of the composition,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248551 - Use as an antiperspirant agent of a flocculating water-soluble polymer; cosmetic process for treating perspiration: The present invention relates to the use of a flocculating water-soluble polymer comprising amine groups borne by a side substituent directly attached to the main chain, as an antiperspirant active agent in a cosmetic composition and particularly in a cosmetic composition not containing any antiperspirant aluminum and/or zirconium salts. The... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248556 - Administration of c-glycoside compounds for activating and regulating cutaneous immunity: e

20070248555 - Composition and method for managing redness of skin associated with dermatological condition: The present invention is directed towards a topical composition for managing redness of skin associated with a dermatological condition, comprising water, gelled ethyl alcohol (an anti-bacterial), anti-oxidants, thickening agents, emulsifiers, stabilizers, and a natural esterified anti-inflammatory (Hepes). This combined therapy is more effective than anti-bacterial agents alone and is particularly... Agent: H. Jay Spiegel - H. Jay Spiegel & Associates

20070248558 - Hair styling composition in the form of a microemulsion: The compositions of the present invention relate to improved hair styling compositions in the form of microemulsions which are non-fluid and clear or transparent and which are comprising 20% to 60% by weight water; at least 3% by weight of an oil phase comprising liquid hydrophobic oils, at least 20%... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248559 - Use of a complex nutritional base in cosmetics, in particular for the hair: The invention concerns a non-therapeutic treatment of the hair and/or the scalp for men and women, wherein it consists in locally applying at the surface of the scalp a complex nutritional base in aqueous medium, comprising at least one fraction of amino acids, one fraction of water soluble vitamins, one... Agent: The Firm Of Hueschen And Sage

20070248560 - Cosmetic product comprising at least one cyanoacrylate monomer and at least one non-ionic polyurethane: Disclosed herein is a cosmetic product for treating keratin fibers, for example, human keratin fibers such as the hair, comprising at least one polymerizable cyanoacrylate monomer, and at least one non-ionic polyurethane, wherein the at least one polymerizable cyanoacrylate monomer and the at least one non-ionic polyurethane may be present... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248554 - Hair style control agent: wherein R2 represents a linear or branched alkyl group having 8 to 18 carbon atoms, and n represents an integer of 1 to 25. The first hair style control agent of the present invention may permanently straighten naturally curly/unruly hair, without damaging or providing a dry feeling to the hair.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070248562 - Stable multiphase composition comprising alkylamphoacetate: The multiphase personal care composition of the present invention comprises a first phase and a second phase. The first phase is comprised of structured surfactant phase that comprises at least about 0.5% of alkylamphoacetate. The alkylamphoacetate comprises a Percentage Diacetate of less than about 15%.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248563 - Skin care compositions including marine extracts: Skin care products, such as depilatories and epilatories, including marine extract blends are provided. The skin care products include one, two, or more of the following marine extracts, in any combination: Enteromorpha Compressa extract, Fucus Vesiculosus extract, Porphyra Umbilicalis extract, Undaria Pinnatifida extract, and Lithothamnium Calcareum extract.... Agent: Fish & Richardson P.C.

20070248565 - Pharmaceutical preparations comprising corticosteroids and antiinfective agents: The invention consists of a stable preparation of a combination drug, comprising of an anti-inflammatory agent and an anti-infective agent. The anti-inflammatory agent in this invention is a corticosteroid, and the anti-infective agent is a derivative of quinolone, amino-glycoside or their pharmaceutically acceptable salts. The combination drug essentially comprises of... Agent: Merchant & Gould PC

20070248566 - Antimicrobial polyisocyanate and derivatives thereof: The present invention discloses an antimicrobial polyisocyanate and derivatives thereof, wherein a quaternary amine is added into the polymerization reaction of a polyol and a NCO-containing isocyanate/poly-isocyanate to form the antimicrobial polyisocyanate; then, the antimicrobial polyisocyanate is added into a functional resin to form an antiseptic material. As the bactericide... Agent: Birch Stewart Kolasch & Birch

20070248568 - Aqueous wildlife attractant, cover scent, and browse supplement: Wildlife enthusiasts and hunters use attractants to increase their chances of being in the presence of desirable wildlife at a designated location. Enthusiasts and hunters use cover scents to mask the human odor thereby helping to prevent scaring the desired wildlife from a designated location. Enthusiasts and hunters use browse... Agent: Williams Family Law Firm, L.L.C.

20070248569 - Eye-drop vaccine containing copolymer 1 for therapeutic immunization: The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070248571 - Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus: An ejection liquid capable of being stably ejected based on a system using thermal energy even if the liquid contains at least one selected from the group consisting of proteins and peptides, and a method and an apparatus for ejecting the liquid containing at least one selected from the group... Agent: Fitzpatrick Cella Harper & Scinto

20070248572 - Method for treating diseases with omega interferon: A method of treating an immunologic, proliferative, or infectious disease in a warm-blooded animal is disclosed. The method comprises administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal, which dosage and activity for... Agent: Barbara G. Mcclung, Esq. Vice President General Counsel And Corporate Secretary

20070248570 - Pharmaceutical compositions containing platinum complexes with secondary xanthates and therapeutic uses thereof: Described are platinum complexes with secondary xanthates and therapeutic uses thereof for treating tumors and autoimmune diseases.... Agent: Klauber & Jackson

20070248580 - Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue: Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that... Agent: Moore & Van Allen PLLC

20070248578 - Mrna transfected antigen presenting cells: A method of amplifying RNA to obtain RNA molecules that are predominantly in the sense orientation and essentially devoid of RNA molecules that are in the anti-sense orientation. A method of transfecting antigen presenting cells with a composition comprising sense RNA encoding immunogenic antigens and essentially devoid of antisense RNA... Agent: Merix Bioscience, Inc.

20070248579 - Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome: This invention relates to the use of secreted SF01-SF13 proteins, to the use of polynucleotides encoding these, and to the use of effectors/modulators thereof in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes mellitus), obesity and/or metabolic syndrome and to the use in regeneration of tissues such... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070248581 - Mgra is a redox regulator of antibiotic sensitivity and virulence: The present invention relates to the identification of a specific cysteine (Cys) residue in MgrA of Staphylococcus aureus and homologs in other bacteria that acts as a redox switch to regulate virulence of S. aureus and expression of bacterial genes that confer resistance to antibiotics. In addition, MgrA is found... Agent: Fulbright & Jaworski L.L.P.

20070248582 - Lactic bacteria and their use in the prevention of diarrhea: The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourista”. The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492 Lactobacillus casei and a mixture... Agent: Godfrey & Kahn S.c.

20070248583 - Novel strains belonging to the genus paenibacillus and method of controlling plant disease by using these strains or culture thereof: Novel strains Paenibacillus sp. BS-0048, Paenibacillus sp. BS-0074, Paenibacillus polymyxa BS-0105 and Paenibacillus sp. BS-0277 and Fusaricidin A, Fusaricidin B and novel compounds 3 and 4 produced thereby have an activity of inducing resistance to plant diseases. Thus, they can protect plants from infections with fungi, bacteria, viruses and so... Agent: Sughrue Mion, PLLC

20070248573 - Chimeric bacteriophages, chimeric phage-like particles, and chimeric phage ghost particles, methods for their production and use: The objective of the present invention is to provide chimeric phage-derived particles, that may be used as safe food grade vehicles to for presenting various factors (e.g. antigens, virulence proteins, receptors, ligands, etc.) for living cells. In addition to at least one normal phage or virus component the particles comprise... Agent: Nixon & Vanderhye, PC

20070248575 - Bone graft composition: The invention provides methods of making a bone graft composition. Also featured are methods of treatment using the bone graft composition and articles of manufacture that include the bone graft composition.... Agent: Fish & Richardson P.C.

20070248577 - Methods and compositions for administering stem cells: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the... Agent: Biotechnology Law Group C/o Portfolioip

20070248574 - Methods of making and using skin-derived stem cells: The present invention describes a method for isolating skin derived precursor stem cells from hair follicles or dermal papillae and also describes the use of these cells for inducing hair growth.... Agent: Clark & Elbing LLP

20070248576 - Regulation of the serotonin reuptake transporter and disease: Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus,... Agent: Viksnins Harris & Padys Pllp

20070248584 - Immunomodulating compositions, uses therefore and processes for their production: The present invention relates to the use of at least one set of peptides in compositions and methods for modulating an immune response to one or more polypeptide antigens. In certain embodiments, the sequences of a respective set of peptides are derived in whole, or in part, from a single... Agent: Proskauer Rose LLP

20070248585 - Methods of regulating renalase (monoamime oxidase c): The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070248586 - Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same: Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also... Agent: Sheridan Ross PC

20070248587 - Wet wipes including a composition for reduction and prevention of wrinkles on the skin: Wet wipes comprising a composition for reducing and preventing wrinkles on the skin is disclosed. The composition is provided in the form of an aqueous composition comprising containing papain, urea, boric acid, preservatives, the sodium salt of 2-pyrrolidone-5-carboxylic acid, and almond extract.... Agent: Gordon & Rees LLP

20070248593 - 32 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070248592 - Agent for inhibiting proliferation of neural stem cells: The object of the present invention is to provide methods for inhibiting proliferation of neural stem cells, an agent for inhibiting proliferation of neural stem cells, and methods for using the same. According to the method of the present invention, a galectin-1 inhibitor such as anti-galectin-1 antibody and/or an integrin... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248594 - Cxcr1 and cxcr2 chemokine antagonists: e

20070248590 - Modulators of cdc2-like kinases (clks) and methods of use thereof: Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070248588 - Novel compositions and methods for the treatment of immune-related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20070248591 - Preventive/therapeutic drug for arteriosclerosis: The present invention provides preventive/therapeutic agents for arteriosclerosis, diabetes mellitus, etc., which comprise glucosylceramide or (and) lactosylceramide synthase inhibitors, expression inhibitors for glucosylceramide or (and) lactosylceramide synthase genes, methods and kits for screening the preventive/therapeutic agents, and so on.... Agent: Foley And Lardner LLP Suite 500

20070248589 - Spatial for altering cell proliferation: This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte numbers in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits SPATIAL activity. Also provided are methods useful for increasing thymocyte number in a subject by administering an... Agent: Klarquist Sparkman, LLP

20070248595 - Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy: The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.... Agent: Baker Botts L.L.P.

20070248596 - Transgenic ficus, method for producing same and use thereof: The present invention relates to transgenic Ficus plants, particularly Ficus carica (fig tree), to a method for producing same, and to Ficus plants, plant materials and plant products produced by or from such genetically modified plant material. More specifically, the present invention relates to transgenic Ficus carica plants and use... Agent: Martin D. Moynihan Prtsi, Inc.

20070248600 - Glycosylated antibodies: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1%... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070248597 - Methods of decreasing vascular calcification using il-1 inhibitors: The present invention relates to methods of decreasing, inhibiting, or preventing vascular calcification in subjects by administering IL-1 inhibitors. IL-1 inhibitors useful in this invention include anakinra, IL-1 antibodies, IL-1 RI antibodies, IL-1 trap molecules, soluble IL-1 receptors, and anti-IL-1/IL-1R peptides and peptibodies.... Agent: Amgen Inc.

20070248598 - Recombinant anti-vla4 antibody molecules: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites... Agent: Fish & Richardson

20070248599 - Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor: Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β peptide (Aβ) in the brain. Aβ is derived from amyloid precursor protein (APP) by β- and γ-secretases. Apolipoprotein E receptor 2 (ApoER2) is a cell-surface receptor for apolipoprotein E. This study shows that ApoER2 interacts with X11α/β proteins and that... Agent: Fulbright & Jaworski L.L.P.

20070248602 - Fc variants having increased affinity for fcyrllc: The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070248603 - Fc variants with increased affinity for fcyrlla: The present invention relates to Fc variants having increased affinity for FcγRIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070248601 - Non-human transgenic mammal for the constant region of the class a human immunoglobulin heavy chain and applications thereof: The invention relates to a non-human transgenic mammal with an IgH locus modified by replacement of the switching sequence S?, with all or part of a transgene comprising the gene Cα of a class A human immunoglobulin, including at least the exon, coding for the CH3 domain and the membrane... Agent: Lowe Hauptman Ham & Berner, LLP

20070248604 - Anti-fgf19 antibodies and methods using same: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.... Agent: Genentech, Inc.

20070248605 - Fibroblast growth factor receptors 1,2,3, and 4 as targets for therapeutic intervention: A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070248606 - Treatment of alzheimer's disease: The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with... Agent: Young & Thompson

20070248607 - Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells: The present invention relates to methods of treating immune disorders, particularly autoimmune diseases and cancers having an immune-deficient aspect involving NKG2D-positive CD4+ cells. In addition, the invention provides screening methods that assess the ability of compositions to modulate the negative immunomodulatory effects of NKG2D-positive CD4+ cells. Also provided is a... Agent: Fulbright & Jaworski L.L.P.

20070248608 - Monoclonal antibodies to progastrin: The present invention provides progastrin-binding molecules specific for progastrin that do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly), or glycine-extended gastrin-34(G34-Gly). Further, the invention provides monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin and the hybridomas that produce these MAbs. Also... Agent: Fish & Richardson, PC

20070248610 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20070248611 - Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist: This invention relates to methods for treating unwanted body weight loss (such as with cachexia and with aging), eating disorders (such as anorexia nervosa), or opioid-induced emesis by peripheral administration of a trkB agonist. The invention also relates to compositions and kits comprising a trkB agonist.... Agent: Pfizer Inc.

20070248609 - Therapeutic method: The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the... Agent: Scully Scott Murphy & Presser, PC

20070248612 - Isolated plasma and method for hyperimmunisation and plasma collection: The present invention relates to isolated canine animal plasma, a method for isolating canine animal plasma, plasma obtained form an immunised or hyperimmunised canine animal and treating a canine animal with the isolated canine animal plasma. The method includes the step of selecting a canine animal having a blood group... Agent: Hoffmann & Baron, LLP

20070248613 - Human antibodies interacting with hiv gp41: Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which... Agent: Merck And Co., Inc

20070248615 - T helper cell epitopes: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of SSKTQTHTQQDRPPQPS (SEQ ID NO: 1); QPSTELEETRTSRARHS (SEQ ID NO: 2); RHSTTSAQRSTHYDPRT (SEQ... Agent: Nixon & Vanderhye, PC

20070248614 - Vaccination: The present invention relates to the use of a 1H-imidazo[4,5-c]quinolin-4-amine derivative as an adjuvant for use with nucleic acid vaccination.... Agent: Glaxosmithkline Corporate Intellectual Property

20070248616 - Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and... Agent: Knobbe Martens Olson & Bear LLP

20070248617 - Medical uses of carrier conjugates of non-human tnf -peptides: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising—a VLP and a particular peptide derived from a polypeptide from the TNF-superfamily linked thereto for use in the production of vaccines for the treatment of autoimmune... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070248618 - Tat-based vaccine compositions and methods of making and using same: A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070248619 - New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use: The present invention relates to a new pharmaceutical composition from natural materials belonging in traditional Chinese medicine and to its preparation method. Said new pharmaceutical composition comprises Astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf. At first, astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf are... Agent: Andrews Kurth LLP Intellectual Property Department

20070248620 - Method of treating malignancies and viral infections and improving immune function with a dietary supplement: Provided herein is a dietary supplement comprising as its active ingredients soybean, mushroom and mung bean is used in a method to treat non-small cell lung carcinoma (NSCLC). The active components of the dietary supplement include phytoestrogens, β-glucans, saponins, inositol hexaphosphate, and lectins.... Agent: Morrison & Foerster LLP

20070248621 - Food product containing policosanols: The invention provides a novel composition and method for reducing “bad” cholesterol and increasing “good” cholesterol. The composition of the invention comprises a food product having sugar cane juice. The sugar can juice preferably contains policosanols. A method of preventing or treating cardiovascular disease comprising administering a composition comprising sugar... Agent: Occhiuti Rohlicek & Tsao, LLP

20070248622 - Attenuated francisella bacteria: In one embodiment, there is disclosed a method of inducing an immune response in a subject comprising administering to the subject a Francisella bacterium that includes an alteration in the nucleic acid sequence encoding the mglA, iglA, iglB, iglC, or iglD gene of the bacterium.... Agent: Fulbright & Jaworski L.L.P.

20070248623 - Gene construction, vector and dna vaccine for the vaccination of aquatic animals: The gene construct comprises a nucleic acid sequence that encodes an immunogenic peptide of an aquatic animal pathogen under the control of an expression control sequence that can direct the expression of said immunogenic peptide in an aquatic animal and which comprises the sequence of a cytomegalovirus (CMV) promoter joined... Agent: Ostrolenk Faber Gerb & Soffen

20070248624 - (1,10b-dihydro-2-(aminocarbonyl-phenyl)-5h-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors: The present invention relates to 5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as inhibitors of the viral replication of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present HIV inhibitors with other anti-retroviral... Agent: Philip S. Johnson Johnson & Johnson

20070248625 - Peptide originating from vaccinia virus: A vaccine for preventing or treating Orthopoxvirus infection that induces a protective or therapeutic immune response, wherein the vaccine comprises (1) an amino acid sequence of 20 amino acid or less (preferably 12 amino acid or less and most preferably 11 amino acid or less) of the formula X1-SEQ ID... Agent: Quarles & Brady LLP

20070248626 - Recombinant toxin fragments: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070248627 - Gene therapy for tumors using minus-strand rna viral vectors encoding immunostimulatory cytokines: The present invention provides methods for treating tumors, which comprise the step of administering into tumor sites a minus-strand RNA viral vector encoding an immunostimulatory cytokine or cells introduced with the vector. The present invention also provides compositions for treating tumors, which comprise as an active ingredient the minus-strand RNA... Agent: Clark & Elbing LLP

20070248628 - Immunogens in cancer stem cells: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially cancer stem cells. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer cells, especially cancer stem cells.... Agent: Lorraine H. Keller Immunotope Inc.

20070248629 - Pharmaceutical formulations for iontophoretic drug delivery: The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of acyclovir (ACV) to at least one target tissue. The present invention also provides methods of treating viral infection in at least one target tissue of a patient by iontophoretically delivering a formulation of the invention... Agent: Elmore Patent Law Group, PC

20070248630 - Pharmaceutical formulations for iontophoretic methotrexate delivery: Pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of methotrexate to at least one target tissue are described and methods for administering methotrexate via iontophoresis.... Agent: Elmore Patent Law Group, PC

20070248633 - Compositions containing a hydroxylated diphenylmethane compound, methods of use: where formula variables are defined in the body of the application and claims and (b) at least one ingredient promoting the solubilization, stabilization and/or activity of the hydroxylated diphenylmethane compound of formula (I). The invention also relates to a cosmetic method for caring for or making up the skin, comprising... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070248631 - Cosmetic composition and cosmetics: Liquid cleansing oils capable of mixing well with old makeup and being easily rinsed off with water have come into the mainstream in recent years. An object of the present invention is to provide a cosmetic composition which easily mixes with old makeup, enables the old makeup to be lifted... Agent: Wood, Herron & Evans, LLP

20070248634 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070248632 - Highly concentrated self- emulsifying emulsion bases used for the production of oil-in-water emulsions: Emulsions suitable for use in cosmetic and pharmaceutical compositions are disclosed. Various substrates for body care, such as wipes and pads, are disclosed, which substrates are impregnated with the emulsions. Such treated substrates are suitable for use, for example, in body care, sun protection, antiperspirant and insect repellent formulations. A... Agent: Cognis Corporation Patent Department

20070248635 - Green tea jewelry: A method for making green tea jewelry is provided. The jewelry may be worn as a transdermal source of green tea components used as an alternative to or in addition to ingestion of green tea liquid or solids. Also provided is a kit for providing green tea jewelry in a... Agent: MastermindIPLaw PC

20070248636 - Method for achieving increased effectiveness when using a synthetic pheromone composition to cause mating disruption among insect pests: A method for achieving increased effectiveness when using a synthetic pheromone composition to cause mating disruption among insect pests such as the navel orangeworm. Makes use of automated dispensers such as aerosol dispensers strategically placed throughout and area of treatment such as an orchard or field and configured to initiate... Agent: Dalina Law Group, P.C.

20070248638 - Structurally modified acellular tissue engineering scaffolds and methods of production: Methods are provided for producing a bioscaffold from natural tissues by oxidizing a decellularized tissue to produce a bioscaffold having pores therein. The pore size and porosity is increased to better accommodate intact cells so that live cells can better infiltrate and inhabit the bioscaffold. The bioscaffold may be freeze-dried... Agent: Myers Bigel Sibley & Sajovec

20070248637 - Bioactive agent release coating and controlled humidity method: A coating composition in the form of a one or multi-part system, and method of applying such a composition under conditions of controlled humidity, for use in coating device surfaces to control and/or improve their ability to release bioactive agents in aqueous systems. The coating composition is particularly adapted for... Agent: Surmodics, Inc.

20070248642 - Foam and use thereof: forming a dispersion by mixing i) a solution comprising a soluble polysaccharide and a plasticizer and adding a polysaccharide/gel-forming ion particles or ii) a soluble, preferably immediately soluble, polysaccharide, preferably an alginate, a polysaccharide/gel-forming ion particles, and adding a solvent, said dispersion (ii) further comprising a water soluble plasticizer to... Agent: Patent Administrator Fmc Corporation

20070248639 - Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures: Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing... Agent: Marcia S. Kelbon, Esq. Omeros Corporation

20070248640 - Occlusive implant and methods for hollow anatomical structure: Apparatus and methods for treating a hollow anatomical structure comprises an implant sized for insertion into a hollow anatomical structure. The implant comprises a plurality of loose, bulked fibers. The fibers are formed from one or more bioabsorbable materials. Upon implantation, the apparatus causes a partial occlusion of the hollow... Agent: Knobbe Martens Olson & Bear LLP

20070248643 - Polymerizable emulsions for tissue engineering: Provided are biocompatible viscoelastic solid materials derived from polymerization of fluid water-in-oil emulsions, along with methods of their preparation and methods for their use for tissue engineering applications, including for reforming diseased, damaged or degenerated intervertebral discs by acceptably non-invasive means.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20070248641 - Use of del-1 in hair, bone and cartilage regeneration: Methods and compositions are described enhancing bone density or formation, including for stabilizing bone grafts, bone repair, joint replacement, and cartilage repair that includes providing a composition including Del-1 locally to a site for enhancing bone density or formation, or to a culture or chondrocytes or multipotent chondrocyte precursor cells,... Agent: Wong, Cabello, Lutsch, Rutherford & Brucculeri, L.L.P.

20070248644 - Muller stem cells: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070248645 - Ophthalmic oil-in-water type emulsion with stable positive zeta potential: An ophthalmic oil-in-water type emulsion, which includes colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent, at least one no ionic surfactant, the emulsion having a positive zeta potential and meeting zeta potential stability Test A requirements. Process for making... Agent: Young & Thompson

20070248646 - Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage: Provided are methods for alleviating a symptom of an eye condition by administering to a mammal an amount of azurocidin inhibitor effective to alleviate the symptom of the eye condition.... Agent: Goodwin Procter LLP Patent Administrator

20070248649 - Carbohydrates mixture: A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large... Agent: Bacon & Thomas, PLLC

20070248647 - Erythritol suppression of ghrelin: The present invention provides novel means to make a new food, especially as a result of cooking or baking but also with cold food preparation to dilute the fat in such foods. This new food is the result of eliminating sugar and independent flour in pastry by mixing erythritol and... Agent: Keith E. Kenyon, M.d.

20070248650 - Food products comprising long chain polyunsaturated fatty acids and methods for preparing the same: The present invention includes a food oil composition comprising a blend of a first oil comprising an LC PUFA and a second oil comprising substantially no LC PUFA. The first oil can preferably comprise an omega-3 LC PUFA, an omega-6 LC PUFA or mixtures thereof. The present invention also provides... Agent: Sheridan Ross PC

20070248648 - High protein, fatigue reducing powder: A powdered composition which provides improved muscle growth and helps reduce fatigue, comprising a combination of edible nutritional whey protein, citrulline malate, and at least one branched chain amino acids. The branched chain amino acids are L-isoleucine, L-leucine, and L-valine. The concentration of nutritional protein present in the composition ranges... Agent: Shirley L. Church, Esq. Duckor Spradling Metzger & Wynne

20070248651 - Formulation for treatment of acne: A vitamin, mineral, herbal, and micronutrient treatment for acne via support of the physiologic processes in the body which cause acne is disclosed. It is a targeted formula, designed specifically to address the causes of acne. This specific, unique formulation preferably in a gummy substrate for ease of administration, to... Agent: Thomas M. Freiburger

20070248652 - Nutritional food and feed, compostition, processing and method of use: The present invention relates to means for protecting and incorporating bioactive compounds in food or feed formulations used to enhance the health status and growth performance of human and non-human organisms.... Agent: Martin D. Moynihan Prtsi, Inc.

20070248653 - Hemostatic compositions and methods for controlling bleeding: The disclosure provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions include an article containing cellulose, e.g., cotton gauze, and a cross-linked polysaccharide ionically linked to the cellulose. Methods of making and using the hemostatic compositions are also provided.... Agent: Fish & Richardson P.C.

20070248656 - Topical preparation dispensers and methods of using the same: Topical preparation dispensers and methods of using the same are provided. Aspects of the invention include a topical preparation dispenser having a holder, one or more vertically stacked topical preparations in the holder, and a cap at one end of the holder configured such that upon movement of the cap,... Agent: Bozicevic, Field & Francis LLP

20070248655 - Lenticular shaped protective mouth sore discs: An adherent, soluble oral patch for delivering topical medication in the mouth having a lenticular shape. The structure of the oral patch is formed with a material that remains solid at human mouth temperatures and slowly dissolves or erodes in saliva, such as a network of long molecules such as... Agent: Graybeal, Jackson, Haley LLP

20070248654 - Protective mouth sore discs made with corn starch: An adherent, soluble oral patch for delivering topical medication in the mouth made with corn starch which remains solid at human mouth temperatures and slowly dissolves or erodes in saliva and is hydrophilic.... Agent: Jeffrey T. Haley Graybeal Jackson Haley LLP

20070248657 - Multi-compartment transdermal pain control device: Multi-compartment patches containing skin-permeable forms of pharmaceutically effective amounts of an opioid agonist, an NMDA receptor antagonist and an anti-inflammatory are useful for the transdermal delivery of the active ingredients to alleviate pain.... Agent: Knobbe Martens Olson & Bear LLP

20070248658 - Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers: The subject of this application is the use of film-forming polyurethanes that are used in hair care agents or mixtures of these polyurethanes with other polymers in pharmaceutical preparations for dermal or transdermal administration of active ingredients, as well as patches and pharmaceutical preparations that contain these hair care polyurethanes.... Agent: Millen, White, Zelano & Branigan, P.C.

20070248659 - Individualized cancer therapy: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue... Agent: Bryan Cave LLP

20070248660 - Method for treating warm-blooded vertebrates with halide-free glucosamine-acidic drug complexes: A method of treating a warm-blood vertebrate. The vertebrate may be a human being or a lower animal. The treatment method involves administering to the vertebrate in need of such treatment a pharmaceutically effective amount of a complex of halide-free glucosamine and a therapeutic drug having a pKa of less... Agent: Law Offices Of Jack Matalon

20070248661 - Capsule for releasing agents contained therein at defined points in a body: A capsule is capable of releasing at least one agent that is contained therein by heating at least one heating element under the effect of at least one alternating magnetic field at a defined point in a body, said capsule dissolving when entering in contact with a dissolving liquid. The... Agent: Jordan And Hamburg LLP

20070248662 - Utilization of dialkylfumarates: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in... Agent: Biogen Idec / Finnegan Henderson, LLP

20070248663 - Utilization of dialkylfumerates: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in... Agent: Biogen Idec / Finnegan Henderson, LLP

20070248664 - Oral antimicrobial pharmaceutical compositions: The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.... Agent: Darby & Darby P.C.

20070248665 - Compositions comprising co-precipitate of eplerenone and a water-soluble excipient: Solid compositions for oral administration comprising a co-precipitate of eplerenone and a water-soluble excipient.... Agent: Nixon & Vanderhye, PC

20070248666 - Granules comprising a beta-lactam antibiotic: The present invention relates to granules comprising a β-lactam antibiotic, wherein CH2S(72h)<50 μl of H2S gas per kg of β-lactam antibiotic, wherein CH2S(72h) is the volume of H2S gas above said granules per kg of said β-lactam antibiotic, when a sample of between 3.5 and 4.5 g of said granules... Agent: Nixon & Vanderhye, PC

20070248668 - Pharmaceutical compositions and uses thereof: The invention features pharmaceutical compositions including rifalazil, a surfactant, and a lipophilic antioxidant and methods of use thereof.... Agent: Clark & Elbing LLP

20070248667 - Tannate compositions and methods of use: Compositions comprising an opiate tannate such as, but not limited to, hydrodocone tannate or codeine tannate, alone or in combination with one or more additional active ingredients from the antihistamine, decongestant, expectorant, and/or antitussive categories which are effective when administered orally for the symptomatic relief of cough associated with respiratory... Agent: Sutherland Asbill & Brennan LLP

20070248670 - Tolterodine beads: Controlled release tolterodine beads are formed of a sugar core, an innermost sealcoat layer comprising HPMC, a tolterodine drug layer, and an outer control release layer. The thickness of the hydrophilic HPMC sealcoat layer can be used help modulate the release of the tolterodine drug.... Agent: SynthonIPInc

20070248669 - Oral sustained release formulation: The present invention relates to an oral sustained release formulation comprising a core, a medicinal layer containing vanlafaxine or a pharmaceutically acceptable salt of venlafaxine and a release-modulating layer containing a release-modulating agent. The present invention also relates to a method for preparing an oral sustained release formulation, and to... Agent: Andrews Kurth LLP

20070248671 - Asymmetric membranes for drug delivery devices: The present invention provides an osmotic dosage form comprising a core containing at least one pharmaceutically active ingredient and which also comprises at least one asymmetric membrane coating wherein said coating comprises one or more substantially water-insoluble polymers, and, one or more solid, water-soluble polymeric materials that do not generate... Agent: Pfizer Inc

20070248672 - Indole and azaindole derivatives with antitumor action: Indole and azaindole compounds useful for the treatment of solid tumours and tumours of the blood are described, they being particularly effective in the treatment of drug resistant tumours; these compounds are also able to synergistically enhance the activity of known antitumour drugs. They can hence be used either alone... Agent: Jay S Cinamon Abelman Frayne And Schwab

20070248675 - Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof: The present invention relates to a nanoparticle-protein-hydrogel composite comprising (1) a polysaccharide-functionalized nanoparticle comprising a core composed of a biodegradable polymer, a hydrogel surface layer composed of a biocompatible polymer emulsifier, and a polysaccharide physically bound to the core and/or the hydrogel layer; (2) a protein forming a specific binding... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070248673 - Copper-based fungicide/bactericide: The present invention discloses an improved copper-based fungicide/bactericide composition. The improved composition offers higher biological activity over typical copper-based products, while requiring significantly less copper in the composition. The present invention also discloses methods of making the improved copper-based fungicide/bactericide composition. The present invention further discloses methods of using the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070248674 - Hydrogel interferon formulations: The present invention is related to pharmaceutical Poloxamer hydrogel formulations containing an interferon. In particular, the invention relates to sustained release hydrogel formulations of interferon-beta, method of preparation and use thereof.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070248676 - Use of nitric oxide adducts: The invention provides a method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be... Agent: Wilmerhale/nitromed

20070248677 - Method for treating warm-blooded vertebrates with a salt of a halide-free glucosamine base and a therapeutic drug: A method of treating a warm-blood vertebrate. The verebrate may be a human being or a lower animal. The treatment method involves administering to the vertebrate in need of such treatment a pharmaceutically effective amount of a salt of a halide-free glucosamine base and a therapeutic drug containing at least... Agent: Law Offices Of Jack Matalon

20070248678 - Uniform-sized hydrophilic metal oxide nanoparticles and preparation method thereof: The present invention provides for a metal oxide nanoparticle that contains a metal core, a shell formed on the surface of the core and consisted of the same metal as the core, and an organic compound containing an element capable of covalently bonding with the nanoparticle and a hydrophilic functional... Agent: Darby & Darby P.C.

20070248679 - Vaccine: The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070248680 - Particles for inactivating toxins: The present invention provides for compositions and methods for recognizing toxins in a host. The composition comprising a particle of less than 100 micrometers in diameter having a tag in direct contact with a portion of the particle, the particle comprising a biodegradable polymer and the portion of the particle... Agent: Gardere Wynne Sewell LLP Intellectual Property Section

20070248681 - Solid dispersion preparation: Provided are a granule or a tablet of a solid dispersion that allows a drug in a preparation to be rapidly dissolved without impairing the dissolution of the solid dispersion, and a method for producing the same. More specifically, provided are a granule of a solid dispersion comprising a poorly... Agent: Roberts, Mlotkowski & Hobbes

20070248682 - Solid preparation comprising enteric solid dispersion: Provided are a solid preparation comprising an enteric solid dispersion that allows a drug in the preparation to be rapidly dissolved without impairing the dissolution of the solid preparation, and a method for producing the same. More specifically, provided are a solid preparation comprising a poorly soluble drug, an enteric... Agent: Roberts, Mlotkowski & Hobbes

20070248683 - Novel compositions of fat-soluble substances: The invention relates to novel powderous, water-soluble compositions of fat-soluble substances and aqueous solutions or emulsions thereof, wherein the fat-soluble substance(s) are encapsulated as inner (discontinuous) phase within an outer (continuous) phase of a matrix substance.... Agent: Nixon & Vanderhye, PC

20070248686 - Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same: A suspension of vector particles (PV) based on polyamino acids and have a mean hydrodynamic diameter between 30 and 120 nm, and an insulin load factor of from 5 to 25% of associated insulin volume relative to the polyamino acid volume forming the vector particles. The polyamino acids are double-block... Agent: Patton Boggs LLP

20070248685 - Dry hemostatic compositions and methods for their preparation: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has... Agent: Townsend And Townsend And Crew, LLP

20070248684 - Pharmaceutical formulations of oxcarbazepine and methods for its preparation: The present invention provides a pharmaceutical composition comprising oxcarbazepine and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution. The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multi-modal oxcarbazepine particle size distribution, preferably with an enhanced... Agent: Kenyon & Kenyon LLP

20070248687 - Method and composition for modulation of systemic inflammatory responses syndrome (sirs): The present invention relates to pharmaceutical composition comprising animal venom and using same in a method for the treatment of Systemic Inflammatory Response Syndrome (SIRS) and related pathologies.... Agent: Nath & Associates

20070248688 - Animal repellent composition and method: A method is provided including preparing an animal repellent composition and applying it to vegetation. The animal repellent composition may be comprised of mentha piperita (peppermint oil), hydrogenated vegetable oil, garlic oil, white pepper, and gum arabic as a thickener/emulsifier and natural sticking/adherent agent. Additionally, whole or powdered eggs, vinegar... Agent: Mr. Walter J. Teneza Jr.

20070248689 - Copper lowering treatment of inflammatory and fibrotic diseases: The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate and thiotungstate, and to the use of these agents in... Agent: Medlen & Carroll, LLP

20070248690 - Composition and methods for alleviating symptoms of neurotoxicity: A composition for alleviating symptoms associated with neurotoxicity. The composition may comprise compounds for preventing glutamate mediated neurotoxicity. The composition may include one or more of the following elements: at least one glutamate antagonist, at least one cAMP stimulating agent, at least one antioxidant, vitamin B12, at least one transporter... Agent: Kramer & Amado, P.C.

20070248691 - Antibacterial compositions and method of using same: Antibacterial solution useful as a cleaning agent suitable for cutaneous use by humans or otherwise which is aqueous based, free of alcohol and surfactants and having a quaternary ammonium compound as its principal antimicrobial agent, a number of moisturizing agents and DMDM Hydantoin serving at least as a preservative.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070248694 - Anti-inflammatory properties of a standardized extract from euphorbia hirta (pm-251) activity and for treating conditions of inflammation: An organic extract (PM-251) from a plant, Euphorbia hirta (Euphorbaceae) has been standardized. Agronomical standardization has been achieved on this plant by growing it in eastern North Carolina. Subsequently the PM 251 extract has been chemically and biologically standardized. The standardized extract has been tested for its efficacy as an... Agent: Daniels Daniels & Verdonik, P.A.

20070248692 - Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent.... Agent: Banner & Witcoff, Ltd.

20070248693 - Nutraceutical composition and method of use for treatment / prevention of cancer: The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and/or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally... Agent: Elizabeth Mazzio Florida A & M University

20070248695 - Landscaping, plant potting, and horticulture methods according to the traditional oriental or korean medicine: Plants that are substantially utilized as the medicinal ingredients in a selected single prescription of the traditional Oriental and Korean medicine are planted together in close proximity to each other. The plants provide therapeutic effects to the body of a person breathing the fragrance emitted by the plants and observing... Agent: Ladas & Parry LLP

20070248696 - Composition and method for enhancing neuromuscular facilitation and cognitive functions: A composition and a method for improving neuromuscular facilitation, also known as “muscle memory,” and enhancing cognitive functions, such as memory and mental focus. The dietary supplement, and the method for the administration thereof, increases acetylcholine levels, which improves neuromuscular facilitation. In various embodiments, factors other than increasing acetylcholine levels... Agent: Catalina + Associates, LLC

20070248697 - Opthalmic solutions: A method of preventing a lowering of concentration of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α isopropyl ester, the prostaglandin derivative being contained in an ophthalmic solution as an active ingredient. The method including (i) adding to the ophthalmic solution a nonionic surfactant to inhibit the prostaglandin... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070248698 - Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity: The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.... Agent: Cantor Colburn, LLP

20070248699 - Pesticides: The invention provides the use of loquat kernel to kill, inactivate or repel pests, in particular nematodes. Also provided is a method of killing, inactivating or repelling nematodes, which method comprises providing loquat kernel and applying the loquat kernel to the nematodes or to an area where the nematodes are... Agent: Leydig Voit & Mayer, Ltd

20070248700 - Extractions and methods comprising elder species: The present invention relates to extracts of elder species plant material prepared by supercritical CO2 extractions methods, methods of treating viruses in a subject and methods of inhibiting viral infections in cells thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070248701 - Methods and formulations for inhibiting naturally occurring phosphodiesterase: Methods and formulations for using Tahitian Noni juice for inhibiting naturally occurring phosphodiesterases (PDEs). The present invention relates to Tahitian Noni juice as a PDE inhibitor to increase body energy and reduce allergy and asthma reactions... Agent: Michael F. Krieger Kirton & Mcconkie

20070248702 - Use of cb2 receptors agonists for the treatment of huntington's disease: The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-α-pinene derivatives, and to pharmaceutical compositions comprising these compounds, and to the use of such compounds for treatment and prevention of the onset of genetic neurodegenerative disorders, in particular Huntington's disease.... Agent: Winston & Strawn LLP Patent Department

20070248704 - Herbal extracts of salicornia species, process of preparation thereof, use thereof against tuberculosis: The present invention relates to novel extracts of Salicornia species. The present invention particularly relates to novel extracts of Salicornia species which show antitubercular activity. The present invention also relates to a process for the preparation of novel extracts of Salicornia species with antitubercular activity and also to the use... Agent: Nixon & Vanderhye, PC

20070248703 - Topical phytotherapeutic compound for the treatment of herpes based on uncaria tomentosa and extraction process for obtaining a vegetal extract from uncaria tomentosa: The present invention concerns a phytotherapic compound for the treatment of herpes based on Uncaria tomentosa characterized by the presence of: (a) A therapeutically efficient amount of an Herbal Extract from Uncaria tomentosa (Willd) DC Rubiaceae, (b) a pharmaceutically acceptable vehicle, (c) at least one pharmaceutically acceptable excipient, and, (d)... Agent: Buchanan, Ingersoll & Rooney PC

20070248705 - Agents for activating the transcription factor nrf2 and foods having such function: A composition, an Nrf2 activating agent, and a food according to the present invention comprise isohumulones or isomerized hop extract as an active ingredient. They are useful in treating, preventing, or ameliorating a disease of condition which is treatable, preventable, or ameliorable by the activation of transcription factor Nrf2. More... Agent: Foley And Lardner LLP Suite 500

20070248706 - Compositions and methods for activating toll-like receptor 4: Methods for activating Toll-like receptor 4 via cholesterol-dependent cytolysins isolated from a Gram-positive bacteria are provided. In addition compositions containing an isolated cholesterol-dependent cytolysin or a fragment thereof or a mimetic of the cytolysin or fragment thereof and methods for use of such composition in inhibiting binding and/or interaction of... Agent: Licata & Tyrrell P.C.

20070243131 - Biopolymer system for tissue sealing: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and... Agent: Schwegman, Lundberg & Woessner, P.A.

20070243153 - Prevention or treatment of male pattern baldness method and device: Method and devices for the prevention or treatment of hair loss, particularly male pattern baldness (MPB), are provided. The pressure on the hair follicles is reduced.... Agent: Brinks Hofer Gilson & Lione

20070243130 - Biopolymer system for tissue sealing: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises an alkylated chitosan, a polybasic carboxylic... Agent: Schwegman, Lundberg & Woessner, P.A.

20070243132 - Transdermal delivery of pharmaceutical agents: The present invention generally relates to a vehicle useful for delivering a pharmaceutically active compound including a genetic molecule or composition. More particularly, the present invention provides microemulsions for transdermal delivery of pharmaceutically active agents to a subject.... Agent: Seed Intellectual Property Law Group PLLC

20070243133 - Method of imaging cell death in vivo: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.... Agent: Lahive & Cockfield, LLP

20070243134 - Receptor selective cannabimimetic aminoalkylindoles: Disclosed are cannabimimetic aminoalkylindole compounds and methods for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoids. The disclosed compounds may include radioactive atoms. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological... Agent: Alix Yale & Ristas LLP

20070243135 - Method of treating fetal growth retardation and placental ischaemia and insufficiency: A method for treating intrauterine growth retardation in an animal, such as a human being, is disclosed comprising administration of a lysine composition.... Agent: Notaro And Michalos

20070243136 - Methods and compositions for imaging: The present invention is directed to compositions useful as imaging agents for use in MRI, CT, Gamma-scintigraphy, or optical imaging techniques. Methods and compositions of using the same are described.... Agent: Marshall, Gerstein & Borun LLP

20070243139 - Multivalent constructs for therapeutic and diagnostic applications: The invention provides compositions and methods for therapeutic and diagnostic applications.... Agent: Kramer Levin Naftalis & Frankel LLP

20070243137 - Cell and sub-cell methods for imaging and therapy: Methods are disclosed to rapidly form and load cells and cell-derived vesicles. Loaded materials can include imaging agents, drugs and magnetic particles. Methods are also presented to additionally target the loaded cells or vesicles, leading to new forms of imaging, treatment, diagnosis, and detection by a large number of techniques.... Agent: Abelman, Frayne & Schwab

20070243138 - Hollow microspheres with controlled fragility for medical use: A composition for ultrasonic imaging is described having a microparticle population of controlled fragility. A method of using such composition for imaging a fluid filled cavity, vessel or tissue is described.... Agent: Dechert LLP

20070243140 - Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.... Agent: Andrews Kurth LLP Intellectual Property Department

20070243141 - Mucosal or cutaneous medicinal or hygiene system: A mucosal or cutaneous medicinal or hygiene system, comprising (a) a gas-driven foam dispenser; and (b) a fluid composition comprising (i) as the only foaming agent one or more polysaccharides, gelatins, synthetic polymers selected from the group consisting of ethylene oxide homo- and copolymers having a weight average molecular weight... Agent: The Dow Chemical Company

20070243142 - Dental liquid desensitizing preparation with resistant flow: A composition applied to exposed dentin of a tooth comprising hydroxyethylmethacrylate or HEMA, glutaldehyde, and a thickening agent in aqueous solution. The thickening agent or viscosity enhancing material increases the viscosity of the composition, preventing the composition from moving out of position or dripping on a vertical surface. The present... Agent: Paul A. Fattibene Fattibene And Fattibene

20070243143 - Cosmetic compositions with backbiting silicone polymers: A cosmetic composition comprising Backbiting Silicone Polymer in a cosmetically acceptable carrier.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070243144 - External preparation: The present invention provides an external preparation that contains processed pueraria flower. When the external preparation of the present invention is applied to skin or mucous membranes, then skin quality improving effects (skin beautifying effects) such as preventing chapped skin or preventing wrinkles, the effect of strengthening mucous membrane elasticity,... Agent: Amin, Turocy & Calvin, LLP

20070243148 - Protecting and regenerating composition: The invention relates to a protecting and regenerating composition. This composition comprises an association of a first cosmetically active ingredient comprising a dried vine shoot extract, and a second cosmetically active ingredient comprising a component of the ectoine type. This composition makes it possible to affect anti-ageing cosmetic care and... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070243147 - Skin and/or hair composition containing compounds for increasing the tanning of skin: The invention relates to agents that are to be applied to the skin or hair and contain compounds for intensifying tanning of the skin and increasing melanin synthesis in skin or hair. The invention particularly relates to cosmetic or dermatological preparations. Using said preparations results in inducing and intensifying the... Agent: Greenblum & Bernstein, P.L.C

20070243145 - Surface-modified metal oxides, method for producing them, and their use in cosmetic preparations: e

20070243146 - Vitamin k1 as energizer in cosmetic formulations: The invention relates to the use of vitamin K1 as energizer in cosmetic formulations and to specific cosmetic formulations containing vitamin K1.... Agent: Nixon & Vanderhye, PC

20070243149 - Nitrocellulose-based binders for aqueous nail varnishes: The present invention relates to a new aqueous binder system for nail varnishes, based on nitrocellulose-containing polyurethanepolyurea dispersions.... Agent: Bayer Material Science LLC

20070243150 - Methods and products for plumping lips of human beings: Methods for plumping human comprise applying topically a first composition that includes one or more blood circulation enhancing substances, and then applying a lip gloss that also includes one or more of such substances.... Agent: Kenneth J. Hovet Nordman, Cormany, Hair & Compton LLP

20070243151 - Nonaqueous gel compositions: The present invention is a non-aqueous cosmetic gel composition of from about 47% to 62% by weight anhydrous gel, from about 17% to about 32% by weight polymer, from about 8% to about 22% by weight ester, and from about 0.001% to about 15% by weight gelling agent wherein the... Agent: Arthur M Dula Law Office Of Arthur M Dula

20070243152 - Formula for fabricating skin treatment product and forming method thereof: The present invention discloses a formula for fabricating skin treatment product, wherein the formula comprises at least one pectin enzyme and at least one cellulose enzyme. The formula is used to mix with an organic mixture to fabricate the desired skin treatment product, and the organic mixture comprises extract or... Agent: Rosenberg, Klein & Lee

20070243154 - Solubilization of acid ingredients: A topical composition containing from 0.5% to 15% by weight of at least one acid having a solubility, in water, at room temperature, of less than 0.002 g/ml, and from 10% to 99% by weight of at least one organic compound, liquid at room temperature, having at least one fatty... Agent: L'oreal Usa/ Patent Department

20070243155 - Skin care method and products: A skin treatment regimen comprising applying to facial skin, in order, at least once per day, effective amounts of five distinct products, including a daily cleanser, an exfoliating masque with thermal infusion, a daily balancer, a daily eye cream and a daily moisturizing cream.... Agent: Kenneth J. Hovet Nordman, Cormany, Hair & Compton LLP

20070243157 - Biodegradable cationic polymers: Polymers comprising a polyethylenimine having a molecular weight less than 600 Daltons, a biodegradable group, and a relatively hydrophobic group that are useful for the delivery of bioactive agents to cells.... Agent: Knobbe Martens Olson & Bear LLP

20070243156 - Synthesis and utilization of peptide mimetics in drug discovery and medicine: The disclosed embodiments are directed to synthesis of peptidomimetic compounds and their utilization in drug discovery and medicine. The disclosed compounds high structural similarities to naturally occurring peptides, but having stability to enzymes and greater bioavailability through their ability to cross biological membranes.... Agent: Mitra Tadayoni-rebek

20070243158 - Skin care compositions and treatments: The invention is directed to compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070243161 - Epigenetic modification of the loci for camta1 and/or foxp3 as a marker for cancer treatment: The present invention relates to a method, in particular an in vitro method, for pan-cancer diagnostics, comprising identifying the amount and/or proportion of stable regulatory T cells in a patient suspected of having cancer through analyzing the methylation status of at least one CpG position in the gene foxp3 and/or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070243160 - Remedies for nerve damages: The present invention provides a remedy for a nerve dysfunctional disorder such as a central nervous system damage including a spinal cord injury and a cerebral infarction and the like having an excellent nerve regeneration promoting action which can be administered not only by injecting into a injured site but... Agent: Morgan & Finnegan, L.L.P.

20070243162 - Specific binding agents for kshv vil-6 that neutrallize a biological activity: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds... Agent: Klarquist Sparkman, LLP

20070243159 - Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules: A therapeutic composition or a vaccine comprising tumor membrane-anchored cytokines or other immunostimulatory or costimulatory molecules are provided. The therapeutic composition or a tumor vaccine can be used for treating a tumor or other disease such as autoimmune disorder, viral diseases, bacterial diseases, parasitic diseases, and transplant rejection.... Agent: Zhaoyang Li Squire Sanders & Dempsey

20070243163 - Respiratory tract delivery of interferon-tau: Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.... Agent: Perkins Coie LLP

20070243165 - Glycosylated g-csf: Granulocyte colony stimulating factor obtained from eggs laid by transgenic avians having newly described G-CSF glycosylation patterns.... Agent: Avigenics, Inc.

20070243166 - Hepatitis c inhibitor compounds: a

20070243164 - Treating skin cancer: This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of cytokines to treat skin cancer are provided.... Agent: Fish & Richardson P.C.

20070243168 - Minigene expression cassette: Methods and compositions for expressing a gene or nucleotide sequence of interest are provided. The compositions include an expression cassette that includes a synthetic enhancer, a transthyretin promoter, and a nucleotide sequence operably under the control of the synthetic enhancer and the transthyretin promoter. The expression cassette may be used... Agent: Perkins Coie LLP

20070243167 - Novel herpes simplex viruses: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding insulin is disclosed. Viruses disclosed are capable of expressing insulin. They may lack neurovirulence and may find use in the treatment of diseases involving abnormal insulin expression or function, such as diabetes.... Agent: Klarquist Sparkman, LLP

20070243176 - Human genes and gene expression products: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g.,... Agent: Chiron Corporation - Intellectual Property - R440

20070243177 - Methods and compositions for treatment of diabetes and related disorders: The present invention provides a method of stimulating growth of a pancreatic islet beta cell and/or enhancing glucose stimulated insulin secretion of a pancreatic islet beta cell, comprising delivering to the cell an exogenous nucleotide sequence encoding Nkx6.1 transcription factor.... Agent: Myers Bigel Sibley & Sajovec

20070243169 - Protein inhibitor of ran activity and methods of use thereof: The invention provides a method of inhibiting Ran protein activity in at least one eukaryotic cell or cell-free extract, the method comprising exposing an amino acid sequence comprising at least a portion of EMCV or TMEV leader protein, wherein the amino acid sequence comprises SEQ. ID NO: 14 or SEQ.... Agent: Quarles & Brady LLP

20070243170 - Targeting of herpes simplex virus to specific receptors: The invention relates to engineered herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a... Agent: Marshall, Gerstein & Borun LLP

20070243171 - Biological cell culture, cell culture media and therapeutic use of biological cells: The protein NM23 is disclosed as an agent for the maintenance of undifferentiated biological cells in culture. The NM23 protein may act as a survival factor for such cultured cells, or to prevent the differentiation and maturation of the cultured cells. The use of NM23 protein is applicable to culture... Agent: Berliner & Associates

20070243173 - Methods and compositions for directing stem cells to the heart: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the... Agent: Biotechnology Law Group C/o Portfolioip

20070243174 - Methods and compositions for directing stem cells to the liver: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the... Agent: Biotechnology Law Group C/o Portfolioip

20070243175 - Methods and compositions for regenerating tissue: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the... Agent: Biotechnology Law Group C/o Portfolioip

20070243172 - Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same: The present invention relates to placenta tissue-derived multipotent stem cells and cell therapeutic agents containing the same. More specifically, to a method for producing placenta stem cells having the following characteristics, the method comprising culturing amnion, chorion, decidua or placenta tissue in a medium containing collagenase and bFGF and collecting... Agent: Intellectual Property / Technology Law

20070243178 - Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use: The present invention provides compositions comprising freeze-dried platelets, microparticles, or both for use as a diagnostic for blood coagulation function. The invention also provides methods of diagnosing or monitoring blood coagulation function, including diagnosing or monitoring blood coagulation diseases and disorders. Kits for performing the methods of the invention are... Agent: LatimerIPLaw, LLP

20070243179 - Methods for treating diseases and increasing longevity: Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20070243180 - Composition containing reduced coenzyme q: It is an object of the present invention to provide a reduced coenzyme Q, as a composition capable of being stably stored and, at the same time, soluble in water, which has not been used for industrial application because of its auto oxidation and lipophilic property. A reduced coenzyme Q-containing... Agent: Brinks Hofer Gilson & Lione

20070243181 - Irak1c splice variant and its use: IRAK 1c splice variants and their preparation and use are described. The splice variants may be used in drug screening assays and methods for diagnosing medical conditions mediated by IRAK1c-modulating activity.... Agent: Philip S. Johnson Johnson & Johnson

20070243182 - Use of carboxypeptidease g for combating antifolate toxicity: A

20070243183 - Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients.... Agent: Novo Nordisk, Inc. Patent Department

20070243186 - Islr gene and its association with osteoarthritis and other bone and cartilage disorders, expression products derived therefrom, and uses thereof: The disclosure relates to the ISLR gene, and functional equivalents thereof, such as those from humans and from mice, probes recognizing the genes, tests to identify such genes, expression products of such genes, uses for such genes and expression products, e.g., in diagnosis (for instance, risk determination), treatment, prevention, or... Agent: Cooper & Dunham, LLP

20070243185 - Polypeptide formulation: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.... Agent: Immunex Corporation Law Department

20070243184 - Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy: The present invention provides methods for reducing the incidence of adverse events related to immunotherapy. More specifically, the present invention provides methods for reducing the incidence of enterocolitis associated with anti-CTLA-4 antibody immunotherapy.... Agent: Baker Botts L.L.P.

20070243189 - Blood vegf level-lowering agent containing il-6 antagonist as the active ingredient: A blood vascular endothelial growth factor (VEGF) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20070243188 - Fc variants having decreased affinity for fcyrlla: The present invention relates to Fc variants having decreased affinity for FcγRIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070243187 - Methods and materials for treating autoimmune diseases and conditions: Disclosed are methods for treating an autoimmune disease or condition in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Also disclosed are methods for suppressing hyperacute graft rejection in a subject. The methods include administering to the subject a compound... Agent: Peter Rogalskyj Rogalskyj & Weyand

20070243190 - Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis: Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to modify apoptosis are also provided.... Agent: Klarquist Sparkman, LLP

20070243191 - Anti-hyperproliferative therapies targeting hdgf: The present invention provides methods of cancer therapy or diagnosis involving targeting hepatoma-derived growth factor (HDGF). In certain embodiments, an antibody and/or siRNA may be used to inhibit HDGF, optionally coupled to or combined with other cancer therapies.... Agent: Fulbright & Jaworski L.L.P.

20070243192 - Growth hormone receptor antagonist cancer treatment: The present invention provides methods and compositions for treating tumorigenic cells (e.g., mammary progenitor cancer cells), with growth hormone receptor antagonists (e.g., Pegvisomant), as well as methods and compositions for screening growth hormone receptor antagonists for their ability serve as anti-neoplastic agents capable of killing tumorigenic cells. The present invention... Agent: Medlen & Carroll, LLP

20070243193 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070243194 - Anti-igf-1r antibodies and uses thereof: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20070243195 - Vaccine against streptococci: The invention relates to subunit immunogenic or vaccine compositions which may comprise at least one polypeptide of Streptococcus equi and methods for preparing and/or formulating such compositions. The invention also relates to the use of such subunit compositions, such as a method for eliciting an immunogenic response or a protective... Agent: Judy Jarecki-black, Ph.d., Esq. Merial Ltd.

20070243197 - Dendrite cells transduced with recombinant adenovirus advcea which generate cea-specific cytotoxic t lymphocytes, vaccine and pharmaceutical composition comprising the same: The present invention relates to an antitumor immune response, and in more detail, to a method for inducing cytotoxic T lymphocytes specific to a tumor-associated antigen that acts specifically on tumor cells. Immunotherapy using the present invention may be most effective among immune therapies that use immunity of our body,... Agent: King & Spalding

20070243196 - Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy: The present invention provides novel vaccine formulations for the treatment of cancer antigens. The vaccine comprises a modified MAGE-3 antigen, a NY-ESO-1 antigen, and an adjuvant comprising a saponin and a immunostimulatory oligonucleotide.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070243199 - Methods and compositions for vaccination of poultry: The present invention provides methods of inducing an immune response against Clostridium species in birds, for protecting birds from Clostridium infection, and/or for protecting birds from related disorders such as necrotic enteritis. The methods can be practiced in ovo and/or post-hatch. The invention further provides compositions and methods for delivery... Agent: Myers Bigel Sibley & Sajovec

20070243198 - Production of biologically active proteins: A fusion protein that is expressed in a recombinant protein body-like assembly (RPBLA) in host eukaryotic cells and organisms is disclosed. More particularly, a biologically active polypeptide fused to a protein sequence that mediates the induction of RPBLA formation is expressed and accumulated in host cells after transformation with an... Agent: Edward P. Gamson

20070243200 - Trehalose producing cells as vaccines: The present invention relates to methods for using prokaryotic cells which have been modified or induced to synthesize trehalose as vaccines and to vaccine compositions obtained thereby.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070243201 - Method for selecting epitopes for immunotherapy: The invention relates to a method for the selection of epitopes for immunotherapy, peptides obtained by said method, the use of said peptides as vaccines and diagnostics and an immune serum obtainable by said method.... Agent: Birch Stewart Kolasch & Birch

20070243202 - Tumor necrosis factor receptor-associated factors: The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.... Agent: Cohen, Pontani & Lieberman

20070243203 - Vaccine for prevention and treatment of hiv-infection: This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag; Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070243204 - Helicobacter pylori proteins useful for vaccines and diagnostics: This invention provides polypeptides of Helicobacter Pylori cytotoxin associated immunodominant (CAI) antigen. The invention also provides prophylactic and therapeutic vaccines comprising polypeptides of Helicobacter pylori CAI antigen, and methods for preparation. The invention also provides methods of treatment of Helicobacter pylori infection using these vaccines.... Agent: Woodcock Washburn LLP

20070243207 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070243205 - Polypeptides for inducing a protective immune response against staphylococcus aureus: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a derivative of a full length S. aureus polypeptide. The full-length naturally occurring polypeptide is referred to herein as full length “ORF0826”. The... Agent: Merck And Co., Inc

20070243206 - Synthetic chimeric fimbrin peptides: The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable Haemophilus influenzae and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by Haemophilus influenzae. The synthetic chimeric fimbrin peptides are synthesized using... Agent: Calfee Halter & Griswold, LLP

20070243208 - Novel chimeric protein for prevention and treatment of hiv infection: This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral... Agent: Klarquist Sparkman, LLP

20070243209 - Compositions and methods for prevention and treatment of fungal diseases: The present invention relates to various pharmaceutical compositions that can be used as active or passive vaccines for the treatment or prevention of fungal disease. Methods for prevention and treatment of infectious and allergic fungal diseases in subjects using the pharmaceutical compositions of the present invention are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20070243211 - Compositions for regulating metabolic disorders and methods of use thereof: The invention relates to compositions comprising a combination of ingredients including one or more oxidative fat metabolizers, neurotransmitters, algin or algin equivalents and medium chain triglycerides that are useful in regulating disorders and maintaining healthy metabolism. The compositions of the invention are useful in enhancing metabolism, burning fat, and enhancing... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070243210 - Methods and products for enhancing energy and nutrition in human beings: Methods for increasing energy in men and women include ingesting internally, twice a day, products that include, for women, multivitamins, multiminerals, high-calcium bone support products, high-ORAC super food products, and enzymes, and, for men, multivitamins, multiminerals, prostate support products, high-ORAC super food products, and enzymes.... Agent: Wagner, Anderson & Bright, LLP

20070243212 - Methods and compositions for vaccination of poultry: The present invention provides methods of inducing an immune response against Clostridium species in birds, for protecting birds from Clostridium infection, and/or for protecting birds from related disorders such as necrotic enteritis. The methods can be practiced in ovo and/or post-hatch. The invention further provides compositions and methods for delivery... Agent: Myers Bigel Sibley & Sajovec

20070243213 - Hbv variants detection and application: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral... Agent: Scully, Scott, Murphy & Presser, P.C.

20070243215 - Adjuvant for dna vaccines: The present invention provides a DNA vaccine useful for treating breast cancer. Generally, the vaccine includes an expression vector that encodes a clinically relevant breast cancer-associated antigenic peptide and an IRM compound. The present invention also provides a DNA vaccine adjuvant that can increase the efficacy of a DNA vaccine.... Agent: 3m Innovative Properties Company

20070243214 - Genes and proteins associated with angiogenesis and uses thereof: Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed.... Agent: Sheridan Ross PC

20070243217 - Film-shaped medicament for oral administration containing estriol: Film-shaped medicaments administered orally, particularly buccally, for treating climacteric complaints. The medicaments contain estriol and/or at least one pharmacologically acceptable ester of estriol, either alone or in combination with at least one gestagen.... Agent: D. Peter Hochberg Co. L.p.a.

20070243218 - Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them: Various pentosan polysulfate (PPS) formulations useful for treatment of osteoarthritis, interstitial cystitis, and other conditions of mammals are provided. These formulations showed improved resistance to degradation and discoloration and improved stability at physiological pH, even after sterilization. Capillary electrophoresis analysis of these formulations indicates that various formulations remain stable under... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070243216 - Stable solutions of prostaglandin and uses of same: Dosage forms of a pharmaceutical composition comprising a sealed actives compartment containing a stable prostaglandin in a pharmaceutical composition for topical application to a patient are disclosed. Preferably, the prostaglandin compound is substantially uniformly dispersed in a delivery vehicle, and in certain embodiments the prostaglandin compound contains stabilizing agent comprising... Agent: Albert T. Keyack Klehr, Harrison, Harvey, Branzburg & Ellers LLP

20070243220 - Cosmetic compositions: A cosmetic composition comprising a crosslinked particulate polyester polyol in a cosmetically acceptable carrier.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070243221 - Anti-wrinkle composition: c

20070243219 - Antioxidant compositions for reducing odor in warming lubricant compositions: This invention relates to the clear, substantially anhydrous, warming compositions containing one or more polyhydric alcohols. The invention also relates to the compositions that include at least one or more antioxidant or antioxidants in combination selected from the group consisting of tocopherol, ascorbic acid and butylated hydroxytoluene (BHT), to prevent... Agent: Philip S. Johnson Johnson & Johnson

20070243222 - Fungicidal formulation and method of use: A method for treating onychomycosis of a nail of an animal, which comprises a topical application of a solution to said nail, wherein said solution is comprised of at least one chemical agent capable of chelating iron metal ions... Agent: Hayes Soloway P.C.

20070243223 - Hygienic and/or cosmetic and/or disinfectant composition including, at least one repulsive and/or repellent vermin-killer agent: The present invention relates to a hygienic and/or cosmetic and/or disinfectant composition including, at least one repulsive and/or repellent vermin-killer agent. According to the invention, the repulsive and/or repellent agent is a fatty acid. The present invention also relates to the use of the composition as a vermin-killer and/or repulsive... Agent: Egbert Law Offices

20070243225 - Drug depot implant designs and methods of implantation: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately... Agent: Fox Rothschild, LLP

20070243226 - Growth factor complex: An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20070243224 - Methods and compositions for treatment of lesioned sites of body vessels: Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide... Agent: Blakely Sokoloff Taylor & Zafman

20070243227 - Coatings for surgical staplers: A material with a first state and a second state is applied to a surgical stapler. The stapler is applied to tissue in a surgical field while the material is in the first state. Subsequently, the second state is achieved by the material to secure the staple line. In some... Agent: Michael Gertner

20070243229 - Degradable therapeutic delivery device: A biodegradable biodelivery device is disclosed. The biodelivery device is formed from a polymer comprising the reaction product of a polyol and a polyacid. When exposed to water, the polymer degrades through hydrolysis. Of particular advantage, the polymer can be formed so as to be elastic and flexible. In one... Agent: Dority & Manning, P.A.

20070243228 - Drug depot implant designs and methods of implantation: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070243230 - Nasolacrimal drainage system implants for drug therapy: Implant devices, systems and methods for insertion into a punctum of a patient optionally comprises a drug core and a sheath body disposed over the drug core. The drug core includes a therapeutic agent deliverable into the eye, and the sheath defines at least one exposed surface of the drug... Agent: Townsend And Townsend And Crew, LLP

20070243233 - Bioactive-rich concentrates and nutritive and therapeutic products containing same: This invention relates generally to the field of compositions for use as nutraceuticals, food additives or adjuncts to conventional drug therapies. In particular, the invention relates to compositions derived from natural oil sources which can be used for effective and inexpensive treatment of cardiovascular diseases, hypercholesterolemia, diabetes, cerebrovascular disease, neurological... Agent: Goodwin Procter LLP Patent Administrator

20070243232 - Method to treat and prevent asthma attacks using throat lozenges and orally-retained liquids containing magnesium: Asthma is an inflammatory disease of the airways in the lungs and bronchial tubes, the lower airway, that impairs breathing, causes wheezing, coughing and excess mucus and phlegm production. Asthma is the source of about one-fourth of all emergency room admissions. Throat lozenges and orally-retained liquids, such as syrups, containing... Agent: George Andrew Eby Iii

20070243234 - Microscopic tagging system for security identification: A microscopic tagging material is provided comprised of a material to which has imparted at least two degrees of identification selected from the group consisting of physical configuration, elemental analysis, functional analysis, and polymeric composition analysis. The material may be a polymeric material, and the tagging material may comprise cut... Agent: Birch Stewart Kolasch & Birch

20070243231 - Use of whey permeate for the treatment of metabolic syndrome: The invention relates to the use of whey permeate, preferably sweet whey permeate and more preferably hydrolysed or partially-hydrolysed sweet whey permeate for the production of a pharmaceutical composition for prophylaxis or treatment of symptoms of metabolic syndrome, type-2 diabetes and secondary diseases, said composition being provided for a mammal.... Agent: Scully, Scott, Murphy & Presser, P.C.

20070243235 - Compositions and methods for producing fermentation products and residuals: The present invention provides compositions and methods designed to increase value output of a fermentation reaction. In particular, the present invention provides a business method of increasing value output of a fermentation plant. The present invention also provides a modified fermentation residual of higher commercial value. Also provided in the... Agent: Wilson Sonsini Goodrich & Rosati

20070243236 - High nutrient concentration feed: An animal diet and method of feeding an animal an amount of different pelleted feed compositions having different amounts of available energy per kilogram of the composition and a different specific ratio of kilocalories total available energy per gram amino acids throughout the animal lifecycles along with the different pelleted... Agent: Banner & Witcoff, Ltd.

20070243237 - Antimicrobial thin film coating and method of forming the same: The antimicrobial thin film coating is a polyelectrolyte complex film applied to a substrate, with the polyelectrolyte complex material having biocidal properties. The polyelectrolyte complex material is formed from a first polyelectrolyte material having a positive charge, which is applied to the substrate in the form of a solution, and... Agent: Litman Law Offices, Ltd.

20070243239 - Patch capable of dispensing a scent: A patch is disclosed which is capable of dispensing a scent. The patch includes a pad impregnated with a liquid and the pad is located between a liquid-impermeable barrier layer and a vapor permeable carrier layer. An evaporative interface is situated between the pad and the carrier layer and represents... Agent: Wilhelm Law Service, S.c.

20070243238 - Treating mouth sores with patches adhered to teeth: A method for treating a mouth sore opposite a tooth by adhering an oral patch on the tooth to speed healing and relieve pain. The oral patch is placed either directly on the portion of the tooth that comes into contact with the sore or is first place onto the... Agent: Graybeal, Jackson, Haley LLP

20070243240 - Transdermal therapeutic system: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal... Agent: Michelle S. Marks Shaw Pittman LLP

20070243242 - Compositions for treating hearing loss and methods of use thereof: This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of genes encoding proteins involved in deafness caused by dominant negative mechanism of action by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such... Agent: Viksnins Harris & Padys Pllp

20070243241 - Silicone vesicles containing actives: A process for preparing a vesicle composition based upon mixing an organopolysiloxane having at least one hydrophilic substituent group, a water miscible volatile solvent, and water is disclosed. The vesicle compositions produced by the method are useful in various personal, household, and health care applications.... Agent: Dow Corning Corporation Co1232

20070243243 - Oral dosage forms including an antiplatelet agent and an acid inhibitor: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor.... Agent: Morgan, Lewis & Bockius, LLP

20070243244 - Methods of treating gastrointestinal tract infections with tigecycline: Disclosed herein are methods of treating at least one bacterial infection, such as lower gastrointestinal infections, comprising orally administering a pharmaceutical composition comprising tigecycline. The composition can take solid or liquid forms, such as solutions, dispersions, or solid forms comprising tigecycline having at least one enteric coating.... Agent: Wyeth/finnegan Henderson, LLP

20070243245 - Oral dosage formulations, methods of preparing the same, and methods of reducing food effects on drug release: A multi-particulate oral dosage form, comprising a plurality of pellets, the pellets comprising a core having disposed thereon a core composition layer, the core composition layer comprising an active agent, and a sustained-release coating disposed on the core composition layer, wherein the sustained-release coating comprises a first polymer comprising a... Agent: Cantor Colburn, LLP

20070243248 - Rapidly disintegrating solid oral dosage form of liquid dispersions: Solid dose rapidly disintegrating compositions for administering pharmaceutical and nutritional supplement agents and methods for the preparation thereof are disclosed and described. Preparation methods which maintain the particulate size of an active agent at the pre-processing size in the final composition are further disclosed. The ability to maintain such particulate... Agent: Thorpe North & Western, LLP.

20070243247 - Dosage form containing the active ingredient cholylsarcosine: The invention relates to a dosage form, containing the active ingredient cholylsarcosine, in the form of pellets, which are provided with a polymer coating that is resistant to gastric juices. The invention is characterised in that it discloses pellets comprising an active ingredient, which contain between 50 and 80 wt.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070243246 - Lubricious coatings for pharmaceutical applications: The invention provides pills and tablets having lubricious coating deposited over the outer surface of the pills and the tablets.... Agent: Dla Piper US LLP

20070243250 - Oral dosage formulations and methods of preparing the same: A method of optimizing a dissolution profile for a selected active agent dosage form, comprises combining a first amount of a first ensemble of pulsed-release pellets having a first dissolution profile with a first T50 and a second amount of a second ensemble of pulsed-release pellets having a second dissolution... Agent: Cantor Colburn, LLP

20070243251 - Dosage forms containing a ppi, nsaid, and buffer: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.... Agent: Steven F. Weinstock Abbott Laboratories

20070243249 - Novel formulation of pyridoxal-5'-phosphate and method of preparation: A pyridoxal-5′-phosphate pharmaceutical formulation suitable for oral administration is provided comprising a dissolution profile, when measured in a standard dissolution apparatus, according to the United States Pharmacopoeia dissolution test, at 37° C. in a 0.05M phosphate buffered solution having a pH of 6.8 at 75 rpm, as follows: (a) greater... Agent: Merchant & Gould PC

20070243252 - Oral dosage formulations and methods of preparing the same: Disclosed herein are methods and compositions suitable for providing zero-order release of active agents. Disclosed herein is a multiparticulate oral dosage form comprising a plurality of pulsed-release pellets, wherein the dosage form releases the active agent at a substantially constant rate following a lag time. The dosage form comprises a... Agent: Cantor Colburn, LLP

20070243253 - Colonic drug delivery formulation: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070243254 - Novel drug compositions and dosage forms of topiramate: The present invention is directed to novel drug compositions and dosage forms comprising said drug compositions. The drug compositions of the present invention comprise a pharmaceutical agent and a solubilizing agent. The drug compositions of the present invention are particularly advantageous for use with low solubility and/or low dissolution rate... Agent: Philip S. Johnson Johnson & Johnson

20070243255 - Multifunctional supramolecular hydrogels as biomaterials: The present invention pertains to the design and application of a supramolecular hydrogel having a three-dimensional, self-assembling, elastic, network structure comprising non-polymeric, functional molecules and a liquid medium, whereby the functional molecules are noncovalently crosslinked. The functional molecules may be, for instance, anti-inflammatory molecules, antibiotics, metal chelators, anticancer agents, small... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070243257 - Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose: The present invention relates to a solid pharmaceutical composition comprising a solid dispersion containing at least one active principle and a pharmaceutically acceptable polymer matrix, a characterized in that said pharmaceutically acceptable polymer matrix comprises a blend of (i) polydextrose, in the form of a continuous polydextrose phase, in order... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070243256 - Polyesteramide platform for site specific drug delivery: A therapeutic agent delivery system formed of a specific type of poly(ester amide) (PEA), a therapeutic agent, and a water miscible solvent is described herein. A method of delivering the therapeutic agent delivery system by delivering the therapeutic agent delivery system formed of a PEA polymer, a therapeutic agent, and... Agent: Blakely Sokoloff Taylor & Zafman

20070243258 - Method and apparatus for forming crosslinked chromonic nanoparticles: An apparatus and method of making crosslinked chromonic nanoparticles includes providing a first aqueous liquid stream including a continuous water-soluble polymer phase and a discontinuous chromonic material phase, providing a second aqueous liquid stream including a salt solution having a multivalent cation, and contacting the first aqueous liquid stream with... Agent: 3m Innovative Properties Company

20070243259 - Nanoparticles for protein/peptide delivery and delivery means: The invention discloses the biodegradable nanoparticle for use in nanoparticle projectile bombardment as a carrier for administering proteins or peptides to an animal subject. The nanoparticles are composed of positively charged shell substrate, negatively charged core substrate with encapsulated bioactive agents of proteins or peptides.... Agent: Hosheng Tu

20070243260 - Treatment of childhood asthma: Glycopyrrolate or an analogue thereof is useful for the treatment of childhood asthma.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070243261 - Biocompatible microcapsules: One of the most prominent amino acids found in biological proteins is aspartic acid. In the present invention L-aspartic acid was heated at 150 deg C for up to 100 hrs to form thermal polyaspartylimide which when heated in boiling water without addition of base hydrolyzed to form thermal polyaspartic... Agent: Peter R. Bahn

20070243262 - Stable s-nitrosothiol formulations: The invention provides stable S-nitrosothiol, such as S-nitrosoglutathione, formulations for long term storage and in vivo delivery of S-nitrosothiols. The invention provides stable aerosol formulations comprising S-nitrosothiol, such as S-nitrosoglutathione, and methods of treating patients in need of S-nitrosothiol, such as S-nitrosoglutathione, and/or nitric oxide treatment.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070243263 - Antiviral methods: Combinations of silver and copper ion sources or a single source of both silver and copper ions are found effective in methods for treating viral infections and for treating surfaces so as to eradicate viral contaminants and/or prevent subsequent contamination of said surfaces with viruses. These methods are particularly applicable... Agent: Edward K. Welch Ii Ip&l Solution

20070243264 - Thickened dilute hypochlorite: This invention relates to methods of thickening dilute hypochlorite and hypochlorous acid compositions. These compositions are thickened with inorganic thickeners, especially synthetic clays. The compositions can additionally contain buffering agents. The compositions show good performance on mold.... Agent: The Clorox Company

20070243265 - System and method for producing massive amounts of elemental iodine: A system and method for extracting active elemental iodine from the contact of water with stored crystal iodine and for introducing the extracted elemental iodine into a water supply line and/or otherwise making the extracted elemental iodine available for an intended use. The system operates by allowing a portion of... Agent: Daniel S. Polley, P.A.

20070243266 - Fluorinated 4-azasteroids as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20070243267 - Zeolitic compositions inhibiting bacillus anthracis toxins: Methods of preparing and using natural or synthetic zeolitic compositions therapeutically to alleviate, cure, or even preclude human host indisposition from exposure to bacteria within the Bacillus anthracis group: namely, B. anthracis, B. cereus, B. Mycoides, and B. thurigiensis. Exposure to bacilli of the first member of that group causes... Agent: Charles A. Mcclure

20070243268 - Compositions for regulating intestinal disorders and methods of use thereof: The invention relates to compositions comprising one or more prebiotics (e.g., one or more dietary fibers) in combination with selenium compounds, flavonoids and/or flavonols, and phosphatides. The invention also relates to methods of regulating disorders, specifically disorders of the intestinal tract and related disorders, by administering a composition of the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070243269 - Saponin and preservative compositions and methods: The invention is related to methods and compositions for improving feeding and/or production characteristics in animals. In an embodiment, the invention includes a method for improving feeding characteristics of an animal including administering a first composition comprising an effective amount of saponins to the animal, and administering a second composition... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20070243270 - Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals: Methods of reducing cellular damage are described that include (a) administering to the mammal an oral dosage form comprising a therapeutically effective amount of a first antioxidant, and (b) administering to the mammal a topical dosage form comprising a therapeutically effective amount of a second antioxidant, wherein at least one... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070243271 - Use of polyphenols to treat skin conditions: A composition is provided to treat and/or prevent for treating skin conditions including fine lines and wrinkles, acne rosacea, surface irregularities of the skin and hyper-pigmentation melasma of the skin, which includes use of a topically applied composition such as an ointment, lotion, cream, serum, gel or pad applied formulation,... Agent: Alfred M. Walker

20070243272 - Method for treating colon cancer with rice bran composition: A nutritional fiber derived from stabilized rice bran is described, which is beneficial for treating colon cancer in an individual. Methods for decreasing the likelihood of colon cancer are also described.... Agent: Townsend And Townsend And Crew, LLP

20070243273 - Reduction of the deleterious effects of tobacco smoking: The invention features a method for inhibiting or reducing the deleterious effects of tobacco smoking including increased incidence of cancers, cardiovascular diseases, various lung disorders and the oxidative effects. The method includes the incorporation of an effective amount of a compound or a standardized plant extract that is that comprises... Agent: Passe' Intellectual Property, LLC

20070243274 - Compositions containing a nopal cactus isolate and method for making same: Compositions and methods of making compositions containing nopal cactus isolates derived from the juice and/or soluble solid fractions of nopal pads. In another aspect, the invention relates to compositions for making coffee, coffee compositions and methods of making such compositions, which contain nopal cactus isolates.... Agent: Hoffmann & Baron, LLP

20070243275 - Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear: The instant invention provides methods and compositions for the treatment of infection or infectious colonization of the eyelid and/or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20070237720 - Embolic prosthesis for treatment of vascular aneurysm: The invention relates to an implantable embolic medical device comprising a non-erodible, erodible or biodegradable material. The device preferably comprises one or more longitudinal filament members of varying cross sectional shapes which may or may not be coiled to suit a particular clinical need. The embolic device is placed through... Agent: Knobbe Martens Olson & Bear LLP

20070237723 - Treatment of cough with interferon: A method of treating chronic coughing in a patient comprising administering to the patient an effective amount of interferon; a method of treating idiopathic pulmonary fibrosis in a patient comprising orally administering to the patient a composition comprising interferon.... Agent: Barnes & Thornburg LLP

20070237725 - Calcium phosphate complex and salts in oral delivery systems: The present invention relates to oral delivery systems, such as confectionery and chewing gum compositions, and methods for remineralizing tooth enamel in mammals. In particular, the oral delivery systems include a phosphopeptide or phosphoprotein stabilized calcium phosphate or calcium fluoride phosphate complex and a salt selected from calcium salts, phosphate... Agent: Hoffmann & Baron, LLP

20070237726 - Oral care regimens and kits: wherein at least one of steps (a) and (b) is conducted prior to retiring at night. Preferably the regimen comprises as step (c) treating interproximal, gingival and subgingival areas of the oral cavity using an interproximal device selected from dental floss, floss pick, dental tape, and proxy brush, wherein step... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070237729 - Impact of calcium phosphate complex on dental caries: The present invention relates to chewing gum and confectionery compositions and methods for reducing dental caries in mammals. In particular, the compositions may include a gum base or carrier, sweetening agents and casein phosphopeptide-calcium phosphate (CPP-ACP). The compositions may be employed to slow the progression and enhance the regression of... Agent: Hoffmann & Baron, LLP

20070237730 - Cosmetic composition with soft focus properties: A cosmetic composition is provided to achieve a soft focus effect. Imperfections in skin complexion can be hidden. The composition includes a water-insoluble partially hydrated granular starch having an average particle size ranging from about 500 to about 10,000 nm, a spherical alumina having a refractive index from 1.6 to... Agent: Unilever Intellectual Property Group

20070237736 - Hair conditioning cosmetic compositions containing a mixture of amidoamines: Compositions are provided and described herein which include cosmetic and hair conditioning compositions having a mixture of stearamidopropyl dimethylamine and behenamidopropyl dimethylamine. Also provided are methods for conditioning hair using such mixtures.... Agent: Flaster/greenberg P.C. 8 Penn Center

20070237741 - Medical treatment applications of swellable and deformable microspheres: A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070237711 - Method of increasing radiation sensitivity by inhibition of beta one integrin: A method for increasing or monitoring apoptosis in tumor cells by the co-administration of ionizing radiation and an anti-integrin antibody. Increasing apoptosis reduces tumor growth in vivo and in a cell culture model. The antibody is directed against the beta-1 integrin subunit and is inhibitory of beta-1 integrin signaling. Other... Agent: Peters Verny , L.L.P.

20070237712 - Methods of redistributing apical target antigens to detect and treat cellular proliferative disease: Methods of detecting and treating a cellular proliferative in a subject through the use of an antibody and a compound that disrupts the apical trafficking of a target antigen are disclosed. In a one embodiment, the target antigen is PSMA.... Agent: Beyer Weaver LLP

20070237713 - Pcan065 antibody compositions and methods of use: The invention provides isolated anti-PCan065 antibodies that bind to PCan065. The invention also encompasses compositions comprising an anti-PCan065 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PCan065 antibody, as... Agent: Licata & Tyrrell, P.C.

20070237714 - Diagnosis and treatment of tumors: The present invention is directed to methods and compositions for the treatment and diagnosis of neuroectodermally-derived tumors, such as gliomas. The inventive methods of treatment generally include local (e.g., intracavitary) administration of a chloroxotoxin moiety conjugated to a cytotoxic moiety to a patient. Also provided are diagnostic methods for screening... Agent: Choate, Hall & Stewart LLP

20070237716 - Compositions and methods for reverse transcriptase-polymerase chain reaction (rt-pcr) of human b-retrovirus: The invention can be summarized as follows. The present invention provides compositions, methods and kits useful for the amplification of nucleic acid molecules from human β-retrovirus by reverse transcriptase-polymerase chain reaction (RT-PCR). Specifically, the invention provides compositions and methods for the amplification of nucleic acid molecules in a one or... Agent: Winston & Strawn LLP Patent Department

20070237715 - Method and apparatus for tear film measurement: Tear film is measured without contacting the eye by comparing reflectance from the eye when the tear film is undisturbed with reflectance from the eye when the when the tear film is disturbed. If the reflectance levels differ somewhat, it is an indication that a healthy tear film exhibiting good... Agent: Hodgson Russ LLP The Guaranty Building

20070237717 - Methods for selection of subjects for multiple sclerosis therapy: A variety of therapies are used to treat autoimmune diseases such as multiple sclerosis. However, there is no single therapy that can be used to treat all subjects. Thus, a method is provided to determine if a subject with an autoimmune disease, such as multiple sclerosis, will respond to a... Agent: Klarquist Sparkman, LLP

20070237718 - Multi-disciplinary approach to validating or indentifying targets using an in vivo system: The present invention embodies a multi-disciplinary approach to validate or identify targets involved in any given biological process or pathway, such as an immune response, or progression or regression of disease. By introducing a target(s) with, e.g., gene delivery vector(s) or other foreign substance(s) to an in vivo system and... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070237719 - Method and system for monitoring and analyzing compliance with internal dosing regimen: A method and system for monitoring and analyzing compliance with an internal dosing regimen prescribed to be taken in multiple dose forms includes the steps of detecting internalization of a first dose form to generate a first data point, detecting internalization of a second dose form to generate a second... Agent: Thomas Moga Butzel Long

20070237721 - Targeted mr imaging agents: MRI contrast agents that employ paramagnetic agents and chemical exchange saturation transfer (paraCEST) and which are coupled to targeted particulate delivery vehicles provide sufficient concentration of the paraCEST contrast agents to obtain useful images of target tissues or organs. In addition, the image contrast may be switched on or off... Agent: Morrison & Foerster LLP

20070237722 - Neural conduit agent dissemination: A method for agent dissemination using a neural conduit. In one embodiment, agent dissemination is facilitated, for example, by the application of thermal energy, ultrasound energy, radiant energy, electromagnetic energy, or electrical current. As one example, agent may be provided to a sensory organ such as the eye for dissemination... Agent: Wood, Herron & Evans, LLP

20070237724 - Foamable suspension gel: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.... Agent: Nath & Associates

20070237727 - Composition and method of bleaching teeth: Methods of using tooth bleaching gels with a high concentration of peroxide are disclosed. The present invention also provides a method for treating one or more teeth. The method includes steps of applying a desensitizing gel to one or more teeth, applying therapeutically effective amount of a tooth bleaching gel... Agent: Crowell & Moring LLP Intellectual Property Group

20070237728 - Method and composition for dental bleaching: This invention relates to a method for bleaching teeth that have been discoloured by a staining agent. The method comprises the steps of coating an area of at least one tooth to be bleached with a dental bleaching composition and irradiating the coated area with laser energy for a predetermined... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070237731 - Nanoemulsion, production method thereof and cosmetic and dermatological composition containing it: This invention comprehends a nanoemulsion based on an emulsifier ternary system that is stable under different temperature and physical stress conditions, besides being compatible with a great variety of cosmetics ingredients. The production method thereof comprises cold emulsification and homogenization steps, which make possible the incorporation of active oily ingredients... Agent: David M. Ostfeld Adams And Reese LLP

20070237732 - Gelling agent for oil: A compound represented by the following general formula (I), wherein R1 and R2 represent a hydrocarbon group having 1 to 26 carbon atoms, preferably a linear or branched alkyl group, R3 represents a hydrocarbon group having 7 to 10 carbon atoms, preferably a linear or branched alkyl group, n represents... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070237733 - Cosmetic composition of water-in-water emulsion type based on surfactants and cationic polymers: at least 0.5% by weight, relative to the total weight of the composition, of at least one cationic polymer with a weight-average molecular mass of greater than 105, in a water-soluble salt(s)/cationic polymer(s) weight ratio of greater than 4.5. The invention also relates to the use of this composition for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070237734 - Anti-wrinkle cosmetic composition: The present invention relates to adenosine derivatives and methods of treating skin using such derivatives.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070237735 - Anti-aging composition, kit and method of use: An anti-aging composition comprising: (i) at least one biomimetic oligopeptide having a sequence of 20 amino acids or less; (ii) at least one lipoaminoacid; (iii) at least one pentacyclic triterpenoid selected from the group consisting of asiaticoside, madecassic acid, asiatic acid and madecassoside; (iv) at least one antioxidant; and (v)... Agent: Goudreau Gage Dubuc

20070237737 - Formulation and method for a skin treatment for animals: An aqueous composition for treating the skin of an animal is provided, the composition including a moisturizer, an anti-itch agent, a skin conditioner, a hair conditioner, a cleansing agent, and an aromatherapy agent. A method for preparing such a composition as well as a method for using the composition for... Agent: Dla Piper US LLP

20070237738 - Low odor latex paint capable of reducing interior odors: A paint composition, which in some embodiments, has a low odor in the container, while during after application to a surface, and once the paint has dried on a surface is disclosed. A method of making such a paint composition is disclosed. A paint composition and method are also disclosed... Agent: The Sherwin-williams Company

20070237739 - Closed loop catheter photopolymerization system and method of treating a vascular condition: A photopolymerization system includes a catheter having a proximal inflatable member, a distal inflatable member, a fluid delivery lumen, and a fluid drainage lumen. The fluid delivery lumen includes at least one delivery port and the fluid drainage lumen at least one drainage port. The ports are positioned between the... Agent: Medtronic Vascular, Inc.IPLegal Department

20070237740 - Formulations and methods for treatment of inflammatory diseases: The present inventors have developed a novel composition and method for inhibiting inflammation and treating of symptoms of tissue ischemia, including that associated with peripheral and cardiac vascular disease by local administration of a pharmaceutical composition including an effective amount of a poloxamer.... Agent: Townsend And Townsend And Crew, LLP

20070237742 - Process for embolization using swellable and deformable microspheres: A method for embolization treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070237743 - Combination therapies using low-toxicity, long-circulating human interferon-alpha analogs: Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antivial and/or antitumor agents. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human... Agent: Perkins Coie LLP

20070237745 - Sisp-1, a novel p53 target gene and use thereof: The present invention relates to a novel p53 target gene SISP-1 (Stress induced Secreted Protein 1) and a SISP-1 protein encoded by the gene. The SISP-1 protein of the present invention induces apoptosis by interaction with p53. The present invention provides the use of the gene/protein associated with treating abnormal... Agent: Sughrue Mion, PLLC

20070237744 - Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a... Agent: Foley And Lardner LLP Suite 500

20070237753 - Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene: A method for transducing a pathologic hyperproliferative mammalian cell is provided by this invention. This method requires contacting the cell with a suitable retroviral vector containing a nucleic acid encoding a gene product having a tumor suppressive function. Also provided by this invention is a method for treating a pathology... Agent: Townsend And Townsend And Crew, LLP

20070237754 - Transient immortalization: The invention relates to a method for transiently immortalizing cells according to which immortalization proteins are introduced into the cells from outside. The invention also relates to a method for producing cells according to which organ-related cells are transiently immortalized by the exogenous supply of immortalization proteins and are remortalized... Agent: Knobbe Martens Olson & Bear LLP

20070237746 - Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase: The present invention relates to the cosmetic or pharmaceutical use of an extract of a nonfruiting nonphotosynthetic filamentous bacterium in a composition containing a cosmetically or pharmaceutically acceptable medium, as an agent increasing the endogenous synthesis of superoxide dismutase, in particular for preventing and/or limiting the formation of free radicals... Agent: Buchanan, Ingersoll & Rooney PC

20070237755 - Geldanamycin-producing strains, uses thereof and methods of producing same: A use of an inoculum of a geldanamycin-producing strain able to survive in a plant rhizosphere as a biocontrol of common scab affecting the plant and a method for biocontrolling common scab comprising the use of such strain. A biologically pure culture of a Streptomyces strain deposited at the American... Agent: Goudreau Gage Dubuc

20070237756 - Antimicrobial preparations: The invention pertains to a method for preserving food against Gram-negative bacteria comprising adding to the food an antimicrobial preparation comprising glycine and alanine. The invention further relates to the use of said antimicrobial preparations for controlling intestinal flora in humans and animals.... Agent: Oliff & Berridge, PLC

20070237750 - Compositions and methods for promoting hair growth: The present disclosure provides compositions and methods for promoting the growth of hair for cosmetic purposes as well as for treating disorders of hair growth. The compositions are conditioned media obtained from a three dimensional tissue that produces a combination of cellular factors effective to induce, promote, or enhance hair... Agent: Dechert LLP

20070237748 - Enhancement of oligodendrocyte differrentiation: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070237751 - Human cord blood as a source of neural tissue repair of the brain and spinal cord: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in... Agent: The Luther Law Firm

20070237747 - Method for increasing the yield of proliferating primary keratinocytes: Disclosed is a method for cultivating keratinocytes and increasing the yield of proliferating keratinocytes by using fibroblasts the JNK activity of which is eliminated or decreased, the use of said fibroblasts and keratinocytes in wound healing and a method for the identification of a JNK-regulated secretable factor.... Agent: Foley And Lardner LLP Suite 500

20070237752 - Methods and compositions for enhancing engraftment of hematopoietic stem cells: The present disclosure relates to the field of hematopoietic stem cell transplantation. More specifically, methods, compositions and kits for improving engraftment of stem cell transplants by administering myeloid progenitor cells are provided.... Agent: Todde A. Lorenz Dorsey & Whitney LLP

20070237749 - Multi-membrane immunoisolation system for cellular transplant: This invention relates to an immunoisolation encapsulation system that protects cellular transplants and thus allows cell function and survival without the need of immunosuppression. The immunoisolation system is a multi-component, multi-membrane capsule that allows optimization of multiple design parameters independently for reproducible functions in large animals models.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070237757 - Compositions and methods for inhibiting the synthesis or expression of mmp-1: The present invention relates to the specific inhibition of matrix metalloproteinase 1 (MMP-1) using agents which inhibit the synthesis or expression of MMP-1. Such agents are useful for suppressing invasion or metastasis of a tumor cell and in the treatment, prevention and management of cancer.... Agent: Licata & Tyrrell P.C.

20070237759 - Antibodies that bind par-2: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives... Agent: Amgen Inc. Law Department

20070237760 - Detection and treatment of cancer: A method for detecting cancer in a patient. The method comprises the steps of introducing labeled antibodies or labeled AFP to a biological sample of the patient so the labeled antibodies or labeled AFP will react with the AFP receptor binding sites in the biological sample. Next there is the... Agent: Ansel M. Schwartz Attorney At Law

20070237758 - Immunoglobulin fusion protein formulations: The present invention provides compositions of Ig fusion proteins, especially compositions including an Ig fusion protein, a bulking agent, a disaccharide, a surfactant, and a buffer. In one aspect, these compositions are stable under long-term storage or at least one freeze/thaw cycle. The invention also provides methods of preparation of... Agent: Wyeth/finnegan Henderson, LLP

20070237764 - Binding polypeptides with restricted diversity sequences: The invention provides variant CDRs comprising highly restricted amino acid sequence diversity. These polypeptides provide a flexible and simple source of sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as... Agent: Merchant & Gould PC

20070237761 - Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia: The present invention provides the use of an anti-CD44 antibody, a (Fab′)2, Fab, Fab′ fragment thereof, an IgG or IgM isotype thereof, in the preparation of a medicament for eradicating pathological stem cells in cancer therapy, and more specifically in acute myeloid leukaemia therapy.... Agent: Buchanan, Ingersoll & Rooney PC

20070237763 - Compositions and methods for the treatment of cancer: The present invention includes compositions and methods for the treatment of cancers by controlling the type of immune response mounted against the tumor, and more particularly, the treatment of tumors with cytokine antagonists to change the type of helper T cell response and inhibition of angiogenesis, prevention of formation of... Agent: Chalker Flores, LLP

20070237767 - Fc variants having decreased affinity for fcyrllla: The present invention relates to Fc variants having decreased affinity for FcγRIIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070237765 - Fc variants having increased affinity for fcyrl: The present invention relates to Fc variants having Increased affinity for FcγRI, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070237766 - Fc variants having increased affinity for fcyrllla: The present invention relates to Fc variants having increased affinity for FcγRIIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070237762 - Process for concentration of antibodies and therapeutic products thereof: The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products.... Agent: Merchant & Gould PC

20070237768 - Fgf-21 fusion proteins: The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.... Agent: Eli Lilly & Company

20070237769 - Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the... Agent: Wolf Greenfield & Sacks, P.C.

20070237771 - Multicomponent conjugates which bind to target molecules and stimulate t cell lysis: where B may be present or absent, A is a specific binding protein such as an antibody or an antibody binding fragment, or a ligand binding to a receptor present on target cells B comprises at least one molecule to which “A” and “C” bind, such as an avidin/streptavidin complex,... Agent: Fulbright & Jaworski, LLP

20070237770 - Novel compositions and methods in cancer: This invention is in the field of cancer-associated (CA) genes. Specifically it relates to methods for detecting and diagnosing cancer or the likelihood of developing cancer based on the presence or absence of expression of certain genes or proteins encoded by those genes. The invention also provides methods and molecules... Agent: Sagres Discovery Inc. Intellectual Property - R440

20070237774 - Method for using boc/cdo to modulate hedgehog signaling: The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such... Agent: Genentech, Inc.

20070237773 - Human sema4a protein antibodies and uses thereof: The invention relates to a novel costimulatory pathway mediated by a member of the semaphorin protein family, Sema4A, which is selectively expressed on the surface of dendritic cells. In addition, the invention relates to the use of Sema4A protein and protein derivatives in a method for the identification of immunomodulatory... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070237772 - Tumor association of mdl-1 and methods: The invention provides methods for detecting, diagnosing, localizing and imaging tumors. The invention also relates to methods for detecting, diagnosing, localizing, imaging and treating cancer.... Agent: Dnax Research Inc. Legal Department

20070237775 - Anti-ghrelin antibodies: Monoclonal antibodies, including chimeric and humanized antibodies, that bind both acylated and unacylated human ghrelin are disclosed. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Such antibodies and antigen-binding portions thereof are useful for neutralizing ghrelin activity in, for example, a human subject... Agent: Eli Lilly & Company

20070237776 - High affinity human antibodies to human il-18 receptor: An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18Rα), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or... Agent: Regeneron Pharmaceuticals, Inc

20070237778 - Gdf-9/bmp-15 modulators for the treatment of bone disorders: The invention provides methods for treating or preventing bone degenerative disorders. The disorders treated or prevented include, for example, osteopenia, osteomalacia, osteoporosis, osteomyeloma, osteodystrophy, Paget's disease, osteogenesis imperfecta, and bone degenerative disorders associated with chronic renal disease, hyperparathyroidism, and long-term use of corticosteroids. The disclosed therapeutic methods include administering to... Agent: Wyeth/finnegan Henderson, LLP

20070237777 - Transdiscal administration of specific inhibitors of pro-inflammatory cytokines: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070237779 - Binding constructs and methods for use thereof: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgGI hinge region polypeptide having either zero,... Agent: Marshall, Gerstein & Borun LLP

20070237780 - Method of preventing or reducing the risk or incidence of cancer: The Embodiments Disclosed Herein are Directed to Methods of preventing or reducing the risk or incidence of cancer in a tissue, gland, organ, or other cellular mass of a mammal by removing or destroying unwanted cells therefrom using compounds containing or based on peptides described herein.... Agent: Hunton & Williams LLP Intellectual Property Department

20070237781 - Biologically active metal-containing nucleic acids: The invention relates to polymers comprising metal-containing nucleic acid duplexes. Methods of using the metal-containing nucleic acid duplexes to provoke physiological responses in a host animal are provided, such as immunological methods that produce antibodies in the host.... Agent: Townsend And Townsend And Crew, LLP

20070237782 - Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae: A method of immunization, and compositions therefor, are provided for substantially preventing or reducing the symptoms of at least one infectious disease and at least one chronic immune mediated disorder. An immunogenic challenge which supplements the normal childhood immunization schedule can help ensure the proper maturation of the immune system... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070237783 - Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv: The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p17 and p24 proteins. Antigens in... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070237784 - Ides, an igg-degrading enzyme of streptococcus pyogenes: A polypeptide isolated from S. pyogenes is described, having IgG cysteine protease activity. The protease is designated IdeS, Immunoglobulin G-degrading enzyme of S. pyogenes. A polypeptide comprises SEQ ID NO: 1 and variants and fragments thereof having IgG cysteine protease activity or the ability to generate an immune response against... Agent: Nixon & Vanderhye, PC

20070237785 - Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof: The present invention relates to a glycoconjugate, a composition and vaccine comprising the same and to the use thereof for enhancing the immune response in cancer therapy wherein the induction of a humoral or a cellular immune response is sought. The invention also relates to a diagnosis kit and to... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070237786 - Diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being.: Compositions and methods for administering to the diet of humans a composition for inducing rapid weight loss, controlling appetite, managing stress and supporting mental well-being, supporting relaxation, and combating fatigue. A diet supplement comprising Calcium and Potassium double salt of Garcinia Cambogia Extract supplying 60% Hydroxycitric Acid, Gymnema Sylvestre Leaf... Agent: Iovate Health Science Research Inc.

20070237787 - Methods for use of tslp and agonists and antagonists thereof: Methods are disclosed herein for specifically inducing proliferation of CD4+ T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with... Agent: Leydig, Voit & Mayer, Ltd.

20070237788 - Non-live trivalent influenza vaccine for one-dose intradermal delivery: The invention relates to the use of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation, in the manufacture of a one-dose influenza vaccine for intradermal delivery. In particular, the invention relates to the use of split influenza preparations wherein the vaccine comprises at least one non-ionic surfactant... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070237789 - Dna-vaccines based on constructs derived from the genomes of human and animal pathogens: Methods of eliciting an immune response in a subject by administering one or more large genomic DNA fragments are provided. Also provided are methods of identifying sequences encoding antigenic polypeptides. Also provided are vaccine compositions comprising one or more large genomic DNA fragments.... Agent: Foley And Lardner LLP Suite 500

20070237790 - Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Three vaccinia virus CD8+ T cell epitopes restricted by the most common human M.C. class I allele, HLA-A0201, were identified. Each of these epitopes is highly conserved in vaccinia and... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070237791 - Construction of live attenuated shigella vaccine strains that express cfa/i antigens (cfab and cfae) and the b subunit of heat-labile enterotoxin (ltb) from enterotoxigenic e.coli: With the goal of creating a combination vaccine against Shigella and other diarrheal pathogens we have constructed a prototype vaccine strain of Shigella flexneri 2a (SC608) that can serve as a vector for the expression and delivery of heterologous antigens to the mucosal immune system. SC608 is an asd derivative... Agent: Venable LLP

20070237792 - Method for measuring the content of a botulinum toxin in a formulation: A method of measuring the concentration of a bioactive agent is disclosed.... Agent: Squire, Sanders & Dempsey L.L.P.

20070237793 - Anti-bacterial vaccine compositions: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.... Agent: Marshall, Gerstein & Borun LLP

20070237794 - Compounds and methods for diagnosis and treatment of leishmaniasis: Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more Leishmania antigens, or a variant thereof. Additionally, methods of... Agent: Apex Patents, LLC

20070237795 - Cryopreservation of haptenized tumor cells: A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells... Agent: Morgan, Lewis & Bockius LLP

20070237797 - Neural conduit agent dissemination: A method for dissemination of a biocompatible agent using a neural conduit. In one embodiment, agent dissemination is facilitated, for example, by the application of thermal energy, ultrasound energy, radiant energy, electromagnetic energy, or electrical current. As one example, agent may be provided to a sensory organ such as the... Agent: Wood, Herron & Evans, LLP

20070237796 - Stable high pl hydrogel compositions: The invention provides a hydrolytically stable isoelectric hydrogel material having a pi value in the range of 11.5<pI<14, that is comprised of an isoelectric compound having a pI value in the range of 11.5<pI<14. The pI of the isoelectric compound and thus, the pI of the hydrolytically stable isoelectric hydrogel... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070237798 - Hydrophobic agents stably dispersed in oil-in-water emulsions: The present invention pertains to oil-in-water emulsion compositions having hydrophobic materials stably dispersed therein and methods for making such. The preferred method of making the emulsion compositions the formation of two O/W emulsions. A first O/W emulsion is for wetting or otherwise pre-treating the hydrophobic components. Thereafter, the first emulsion... Agent: The Estee Lauder Cos, Inc

20070237801 - Chemoablation of tissue using biodegradable, solid salt dosage forms: Novel methods for the chemical ablation of tissue (e.g. prostatic tissue) are described. These methods include the steps of: (a) providing one or more solid salt dosage form comprising 50-100% w/w salt; and (b) inserting one or more of such solid salt dosage forms into the tissue. The solid salt... Agent: Mayer & Williams PC

20070237800 - Multiphasic biofunctional nano-components and methods for use thereof: Multiphasic nano-components (MPNs) having at least two phases and at least one active ingredient are provided. The MPNs can be used in various methods for medical diagnostics or with pharmaceutical, personal care, oral care, and/or nutritional compositions, for example, in oral care, hair, or skin products. The MPNs can be... Agent: Harness, Dickey & Pierce, P.L.C

20070237799 - Osteogenic composite matrix, method for the production thereof and implant and scaffold for tissue engineering provided with a coating formed by said osteogenic composite matrix: The invention relates to an osteogenic composite matrix consisting of collagen and non-collagen components of an extracellular matrix (ECM-components), to a method for producing said matrix, to a method for producing an implant or a scaffold for tissue engineering which is provided with a coating formed by said osteogenic composite... Agent: Sughrue Mion, PLLC

20070237802 - Inhibition of calcification on an endovascular device: An endovascular device includes a body having a surface, and at least one protein or peptide antagonist of calcification disposed on a portion of the surface. In another embodiment of the invention, an endoluminal device includes a body having a surface, and a coating disposed on a portion of the... Agent: Medtronic Vascular, Inc.IPLegal Department

20070237803 - Biodegradable biocompatible amphiphilic copolymers for coating and manufacturing medical devices: Disclosed in the present invention are biodegradable biocompatible amphiphilic copolymers for coating and manufacturing medical devices. The properties of the polymers in the present invention are fine tuned for optimal performance depending on the medical purpose. Moreover, the polymers of the present invention retain and release bioactive drugs in a... Agent: Medtronic Vascular, Inc.IPLegal Department

20070237804 - Impact of calcium phosphate complex on dental caries: The present invention relates to chewing gum and confectionery compositions and methods for reducing dental caries in mammals. In particular, the compositions may include a gum base or carrier, sweetening agents and casein phosphopeptide-calcium phosphate (CPP-ACP). The compositions may be employed to slow the progression and enhance the regression of... Agent: Hoffmann & Baron, LLP

20070237805 - Calcium phosphate complex in acid containing chewing gum: The present invention relates to chewing gum and confectionery compositions for improving the dental health of mammals, particularly humans. In particular, the compositions may include a gum base or carrier, sweetening agents, casein phosphopeptide-calcium phosphate (CPP-ACP) and food-grade acids. The compositions may be employed to remineralize the tooth surfaces of... Agent: Hoffmann & Baron, LLP

20070237806 - Multi-functional dental composition: This invention relates to novel dental compositions and methods for preventing dental plaque and carie formation and generally for inhibiting tooth decay and brightening/whitening teeth. The compositions of this invention comprise organic acids such as acetic acid and salts thereof which can be combined with pharmaceutically acceptable carriers or diluents... Agent: Vorys Sater Seymour Pease

20070237808 - Therapeutic belt: A therapeutic apparatus having an expanse of material that can be adjustably wrapped around a portion of a user's body and which is securable thereon. Various therapeutic components can be attached to the material expanse in numerous positions, such that when it is secured on the user, the components direct... Agent: Schnader Harrison Segal & Lewis, LLP

20070237807 - Anti-microbial hand towel with time-delay chromatic transfer indicator and absorbency rate delay: A disposable paper towel with an anti-microbial lotion and is provided with a chromatic transfer indicator which undergoes a delayed, visually perceptible color change at a predetermined time after the towel is wetted. An anti-microbial lotion on the towel increases water absorbency times (WAR) to further promote lotion transfer to... Agent: Patent Group Ga030-43 Georgia-pacific LLC

20070237810 - Biocidal fibrous and film materials comprising silver and chlorite ions: Disclosed are compositions comprising a hydrophilic polymer, a hydrophobic polymer, a silver ion, and a chlorite anion, wherein the silver ion associates with at least one hydrophilic or hydrophobic polymer, and wherein the chlorite ion associates with the hydrophilic polymer. Also disclosed are methods of making a photo-stable silver ion... Agent: Fulbright & Jaworski L.L.P.

20070237811 - Chitosan wound dressing: A composition is described in which chitosan is prepared in a foamed gel that may be layered onto a suitable backing for use as a wound dressing, or the gel may be directly applied to wounds to effect hemostatic activity as a result of the action of the chitosan. The... Agent: George H. Scherr, Ph.d.

20070237809 - Multi-functional bioactive wound dressing: A novel, lightweight bioactive wound dressing is provided which offers infection-resistance as well as localized wound healing properties. The wound dressing is comprised of preformed fibrous matter, which is comprised of either a composition which intrinsically provides multiple chemical groups which are functional for subsequent chemical reaction; or is a... Agent: David Prashker David Prashker, P.C.

20070237812 - Multi-layer wound dressings: A wound dressing includes one or more layers containing a first anti-microbial agent and optionally at least one of: a chelating agent, a second anti-microbial agent, a zinc-containing agent, a cell-signaling agent, and an additional active ingredient or agent.... Agent: Buchanan, Ingersoll & Rooney PC

20070237813 - Cancer-suppressing agents: It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof, and a cancer-suppressing agent which comprises NR1I2 protein... Agent: Birch Stewart Kolasch & Birch

20070237814 - Novel encochleation methods, cochleates and methods of use: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo... Agent: Lahive & Cockfield, LLP

20070237815 - Dosage forms and methods comprising amlodipine and chlorthalidone: The subject invention provides compositions and methods of use of a single dosage form which includes therapeutic or subtherapeutic doses of a dihydropyridine calcium channel blocker (CCB), such as amlodipine, and a diuretic, preferably a thiazide-type diuretic, such as chlorthalidone.... Agent: Accu-break Technologies, Inc.

20070237817 - Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use: The present invention provides novel polymorphic and pseudopolymorphic forms of Trandolaprilat, including crystalline Trandolaprilat Form A, crystalline Trandolaprilat Form B, crystalline Trandolaprilat Form C, crystalline Trandolaprilat Form D, crystalline Trandolaprilat Form E, and mixtures thereof. The invention also provides novel methods for producing Trandolaprilat, pharmaceutically acceptable salts of Trandolaprilat, and... Agent: Lord, Bissell & Brook LLP

20070237816 - Acetaminophen formulation for joint pain relief: The invention relates generally to a formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for joint pain relief. The formulation may comprise supplements such as glucosamine, hyaluronic acid and methylsulfonylmethane (MSM) and acetaminophen for acute joint pain. The invention also encompasses methods... Agent: Frommer Lawrence & Haug

20070237818 - Controlled-release formulation of hcv protease inhibitor and methods using the same: Controlled-release dosage formulations including at least one compound of Formulae I to XXVIII herein and a controlled-release carrier and methods of treatment using the same are provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070237819 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20070237820 - Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug: Disclosed is a pharmaceutical dosage form including a therapeutically effective amount of an NSAID and an antiulcerative agent.... Agent: Davidson, Davidson & Kappel, LLC

20070237821 - Nanogel-based contrast agents for optical molecular imaging: wherein X is a water-soluble monomer containing ionic or hydrogen bonding moieties; Y is a water-soluble macromonomer containing repetitive hydrophilic units bound to a polymerizeable ethylenically unsaturated group; Z is a multifunctional crosslinking monomer; m ranges from 50-90 mol %; n ranges from 2-30 mol %; and o range from... Agent: Patent Legal Staff Eastman Kodak Company

20070237822 - Testosterone gel and method of use: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.... Agent: Mayer, Brown, Rowe & Maw LLP

20070237823 - Solid pharmaceutical form comprising and ltb4 antagonist: The invention relates to a solid pharmaceutical form obtainable by melt extrusion comprising an LTB4 antagonist, which is embedded in a polymer matrix (solid dispersion).... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070237824 - Sustained-release preparations of quinolone antibiotics: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.... Agent: Banner & Witcoff, Ltd.

20070237825 - Composition for topical substance delivery: A polymerized hydrogel composition for hydrating or dehydrating a surface, particularly a dermatological surface, to which it is applied and a method for forming the composition. The composition is comprised of a mixture of two polymerizable materials, a two-part redox catalyst system and a two-part polymerization medium. The percentage by... Agent: Feldmangale, P.A.

20070237830 - Microsphere powder of high density, swellable, deformable, durable occlusion-forming microspheres: Highly durable occlusions that are useful for embolic treatment were obtained using microspheres having new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres are provided in a microsphere powder which also has high density and high swell properties, that is... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070237829 - Melanin nanoshells for protection against radiation and electronic pulses: This invention provides melanin nanoshells and their use for protection against radiation, particularly ionizing radiation, and electronic pulses, and methods of making materials comprising melanin nanoshells.... Agent: Amster, Rothstein & Ebenstein LLP

20070237827 - Nanoparticles for drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent of HMG-CoA reductase inhibitors or erythropoietin. The nanoparticles are characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.... Agent: Hosheng Tu

20070237826 - Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides: The present invention encompasses lipid nano/micro particles, which have been modified, preferably on their surface, to contain a molecule or ligand, which targets the nano/micro particles to a specific site. The invention also encompasses the use of the modified lipid nano/micro particles for the oral delivery of drugs and antigen... Agent: Foley And Lardner LLP Suite 500

20070237828 - Ziprasidone dosage form: Pharmaceutical formulations of ziprasidone comprise ziprasidone or a salt thereof, in the form of particles having a mean particle size greater than about 90 μm and a pharmaceutically acceptable excipient.... Agent: Dr. Reddy's Laboratories, Inc.

20070237832 - Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause... Agent: Darby & Darby P.C.

20070237833 - Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause... Agent: Darby & Darby P.C.

20070237831 - Nanoparticles for monoclonal antibody delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent of monoclonal antibody. The nanoparticles are characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.... Agent: Hosheng Tu

20070237834 - Zinc zeolite for the treatment for diaper rash (diaper dermatitis): The present invention provides treatment of infants and incontinent adults related to diaper rash, also known as diaper dermatitis, by the application of divalent metal complexes of zeolites, such as zinc zeolite, and compositions thereof.... Agent: Shyam K. Gupta Bioderm Research

20070237835 - Peritoneal dialysis solution: The present invention relates to a solution for peritoneal dialysis consisting of one or more separate solutions. A treatment free of side-effects with a simultaneous lowering of blood pressure can be achieved in that the solution contains sodium ions in a concentration in the region from 121 to 129 mmol/l,... Agent: Jacobson Holman PLLC

20070237836 - Strontium compound for treatment of sub-dermal soft tissue pain: The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.... Agent: Sughrue Mion, PLLC

20070237837 - Biocompatible tea tree oil compositions: A non-phytotoxic fungicidal composition comprising an alkali or ammonium salt of a high MW organic fatty acid forming an emulsion, and tea tree essential oil, terpinen-4-ol oil solubilized in the emulsion, and a method of producing the aforesaid non-phytotoxic biocide, including the steps of admixing alkali or ammonium salts with... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070237841 - Plant extracts for treating skin disorders and enhancing healing of wounds for diabetic patients: The present invention provides a pharmaceutical composition for treating skin disorders, including enhancing the healing of wounds for diabetic patients. Specifically, this invention relates to the use of the extracts of Plectranthus amboinicus and Centella asiatica for improving skin disorders, including enhancing the healing of wounds for diabetic patients, and... Agent: Ladas & Parry

20070237838 - A herbal composition for treating diseases and a method for obtaining the same: A natural herbal composition for the treatment of cancer, hepatitis C, HIV/AIDS, and Pengifoide Buloso, with the composition comprising a mixture of herbs Artemisa absinthium L. and Ruta graveolens L. in an infusion. A method for preparing the composition is also provided.... Agent: Norris, Mclaughlin & Marcus, P.A.

20070237839 - Compositions and methods for uterine relaxing: A method for treating/relief of women's menstruation pain. The pain is reduced or relieved by externally administering an effective amount of an essential oil obtained from origanum, anthopogan, perrila, herba moslae, elemi, cuban oregano and/or a combination thereof.... Agent: Birch Stewart Kolasch & Birch

20070237840 - Therapeutic gastrodia extracts: This document describes compounds, extracts, and pharmaceutical compositions relating to Gastrodia spp., and methods for the treatment subjects having metabolic disorders or medical conditions such as Huntington's disease, a trinucleotide repeat disease or abnormal blood glucose levels.... Agent: Cohen, Pontani, Lieberman & Pavane

20070237842 - Compositions for safe and effective reversal of stratum granulosum in keratinization disorders: Topical compositions for Safe and Effective regression of Stratum Granulosum in keratinization disorders in the form of ointment, cream, oil, soap and shampoo contain non-aqueous herbal extract of Wrightia Tinctoria, cocos nucifera, and suitable pharmaceutically/cosmetically accepted excipients for dermal use.... Agent: Bregen Technical Consultants L.L.C.

20070237843 - Compositions for herbal teas enriched with dried plant extracts: Disclosed are compositions for herbal teas including at least one plant material for conventional herbal teas and at least one extract in the form of a water-dispersible granulate obtainable by extraction from the material or a different plant material.... Agent: Young & Thompson

20070237844 - Methods for removing contaminants from essential oils: Methods for removing a contaminant from an essential oil comprising contacting the essential oil including the contaminant with an aqueous alkaline solution.... Agent: Sutherland Asbill & Brennan LLP

20070237845 - Methods and materials for reducing or eliminating risk factors associated with syndrome x: A composition containing cinnamon extract reduces and/or eliminates one or more risk factors associated with Syndrome X. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070237846 - Compositions containing a nopal cactus isolate and method for making same: Compositions and methods of making compositions containing nopal cactus isolates derived from the juice and/or soluble solid fractions of nopal pads. In another aspect, the invention relates to compositions for making coffee, coffee compositions and methods of making such compositions, which contain nopal cactus isolates.... Agent: Hoffmann & Baron, LLP

20070237847 - Cosmetic composition comprising an extract of the leaves of the castanea sativa plant and cosmetic treatments: The present invention is concerned with a composition comprising an extract of the leaves of the plant Castanea sativa. It is furthermore concerned with the use of this extract for the manufacture of a cosmetic composition and with the use of this extract for the cosmetic treatment of the human... Agent: Cognis Corporation Patent Department

20070237848 - Morinda citrifolia based compositions for treatment of anti-inflammatory diseases through inhibition of cox-1, cox-2, interleukin-1beta, interleukin-6, tnf-alpha, hle, and inos: Methods and compositions for inhibiting 5-Lipoxygenase, 15-Lipoxygenase, COX-1, COX-2, Interleukin-lβ, Interleukin-6, α, HLE, and iNOS. Methods and compositions for treating and preventing diseases, including inflammatory diseases and skin cancer. Compositions comprising processed Morinda citrifolia components, some of which include leaf extracts, leaf juice, and/or seed extracts.... Agent: Kirton & Mcconkie A Professional Corporation, Attorneys At Law

20070231258 - Peptide conjugates: The present invention relates to a method for synthesizing peptide conjugates comprising a functional peptide, cyclic by means of a lactam bridge; a sulfur-linker bound to said cyclic peptide, wherein said sulfur-linker comprises sulfur or a sulfur-reactive site. The invention further relates to a method for synthesizing peptide-effector conjugates. The... Agent: Buchanan, Ingersoll & Rooney PC

20070231271 - Topical composition of biocellulose as gel, spray-aerosol, cream and/or aqueous for the treatment of epithelial lesions: TOPICAL COMPOSITION OF BIOCELLULOSE AS GEL, SPRAY-AEROSOL, CREAM AND/OR AQUEOUS FOR THE TREATMENT OF EPITHELIAL LESIONS refers to a new pharmaceutical form that uses bacterial cellulose, also known as biocellulose, and that consists of a practical and effective dressing, easy to be applied, specially its composition as gel, cream, spray-aerosol,... Agent: Mccormick, Paulding & Huber LLP

20070231274 - Mouthwash and method of using same for the treatment of mucositis or stomatitis: An oral rinse formulation for the treatment or prophylaxis of mucositis or stomatitis comprises one or more of the following components in combination with pharmaceutically acceptable excipients or additives: a) at least one corticosteroid; b) at least one anti-histamine; c) at least one topical anaesthetic; d) at least one antibiotic... Agent: Blake, Cassels & Graydon LLP

20070231277 - Multicomponent whitening compositions and containers: The present invention is directed to a container for housing and dispensing dentifrice compositions and that includes a first chamber containing therein a first dentifrice composition that includes a non-abrasive whitening agent and at least one thickener, a second chamber containing therein a second dentifrice composition that includes an abrasive... Agent: Philip S. Johnson Johnson & Johnson

20070231278 - Oral care compositions having improved consumer aesthetics and taste: The present invention relates to peroxide containing oral care compositions containing a flavor system that effectively masks the undesirable taste and sensations due to peroxide. The flavor system comprises menthol, at least one other secondary coolant and selected flavor chemicals that together provide a stable flavor profile and a high... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070231276 - Stable dental whitening compositions: The invention is directed to a dental whitening composition including a dental whitening agent, a thickening agent, and a zwitterionic stabilizer in an amount effective to provide improved chemical and/or physical stability to the dental whitening composition.... Agent: Philip S. Johnson Johnson & Johnson

20070231279 - Cosmetic self-tanning compositions: A cosmetic self-tanning composition which comprises dihydroxyacetone and a ginkgo extract and/or grapeseed oil and/or a lotus blossom extract. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20070231297 - Methods related to wound healing: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products... Agent: Linda O. Palladino

20070231300 - Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents: The invention relates to covalent conjugates between endoperoxides and small peptides and organic compounds that bind to molecular cavities on the transferrin or lactoferrin receptor, and the use of compositions comprising these conjugates to treat cancer, hyperproliferative disorders, inflammatory diseases, and infections.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070231301 - Parenteral low dose type 1 interferons for bladder cancer: Novel methods and drug products for treating superficial bladder cancer (SBC) are disclosed, which involve parenteral administration of low doses of a type 1 interferon. The doses used are subtherapeutic for other solid tumors. Use of the novel methods and products in combination with other therapies for SBC is also... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070231307 - Energy assisted stem cell extract: A process utilizing an electromagnetic and mechanical energy to produce tissue damage in small regions of skin without damage to neighboring tissue. This permits healthy physiological responses originating in the neighboring tissue to repair the damaged tissue or to produce new healthy tissue to replace the damaged tissue including stem... Agent: Stemedica Cell Technologies, Inc

20070231305 - Ex vivo generated tissue system: The present invention relates to methods of generating an ex vivo tissue-like system in a bioreactor system capable of supporting continuous production of, and output of cells and tissues and an ex vivo tissue system made therefrom.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070231312 - Nutritional supplement for pregnant females: Preeclampsia and intrauterine growth restriction in a pregnant female mammal are prevented or decreased in severity by administering thereto a combination of a vitamin compound containing B1, Folic Acid (or active form 5-Methyl-Tetrahydrofolate i.e.; Metafolin®), B 6 (Pyridoxine or active form Pyridoxine 5-Phosphate P5P), B 12, Ascorbic Acid, Selenium, Zinc,... Agent: Arthur L. Lessler

20070231313 - Compositions, systems and methods for the diagnosis, prevention and treatment of disorders associated with azetidine-2-carboxylic acid: Methods and systems for detecting azetidine-2-carboxylic acid (Aze) in food consumable by humans and animals are provided. Also provided are methods and systems for inactivating Aze in food and byproducts, as well as other methods for the diagnosis, prevention, and treatment of disorders associated with Aze.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070231255 - Method for the treatment of mammalian skin tissues via pulse irradiation in the presence of a photoactive compound: A method of treating mammalian skin tissues for causing a predetermined physiological change in the mammalian skin tissues. A treatment composition of matter is applied onto the mammalian skin. The mammalian skin is irradiated with a first pulse having a power density above an activation threshold power density and with... Agent: Louis Tessier

20070231256 - Compositions and methods for detecting and treating tumors containing acidic areas: Improved compositions have been developed which are selectively sequestered in acidic areas of tumors. When the compositions contain a radioisotope effective to report the presence of the composition, the compositions are useful for detecting tumors. When the compositions contain radioisotopes effective to kill cells, the compositions are useful for treating... Agent: Teri G. Andrews, Patent Attomey

20070231257 - Gastrin releasing peptide compounds: New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing... Agent: Kramer Levin Naftalis & Frankel LLP

20070231259 - Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production: Isolated nucleic acid molecules, designated SMP nucleic acid molecules, which encode novel SMP proteins from Corynebacterium glutamicum are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SMP nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further... Agent: Lahive & Cockfield, LLP

20070231262 - Hepatitis c virus variants: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070231263 - Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders: The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20070231264 - Mammalian cytokine; related reagents: Purified genes encoding a cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.... Agent: Dnax Research Inc. Legal Department

20070231261 - Nucleic acids and corresponding proteins entitled 251p5g2 useful in treatment and detection of cancer: A novel gene 251P5G2 and its encoded protein, and variants thereof, are described wherein 251P5G2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 251P5G2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 251P5G2 gene or... Agent: Agensys C/o Morrison & Foerster LLP

20070231260 - Transporter-targeted methods of diagnosis and treatment: Methods of treating a disease in a patient, methods of determining the presence of a disease in a patient, methods of determining whether a disease in a patient is suitable to be treated with a therapeutic agent, and methods of monitoring treatment of a disease in a patient comprising determining... Agent: Townsend And Townsend And Crew, LLP

20070231265 - Compositions and methods for dual therapies of hair graying and balding in follicular delivery systems: The present invention provides comprehensive compositions for treating problems associated with hair graying and balding via the incorporation of: (i) the cell growth factor of HSCF to induce the migration of melanocyte stem cells and keratinocyte stem cells and then to increase the growth of melanocytes and keratinocytes in hair... Agent: Pai Patent & Trademark Law Firm

20070231266 - Diagnosis of macrophage mediated disease: where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for... Agent: Barnes & Thornburg LLP

20070231267 - Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen,... Agent: Bacon & Thomas, PLLC

20070231268 - Methods and compositions for deterring abuse of orally administered pharmaceutical products: This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended... Agent: Morgan, Lewis & Bockius LLP

20070231269 - Analgesics: An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which... Agent: Nixon & Vanderhye, PC

20070231270 - Biopolymer and gene complex: Disclosed herein is a biopolymer/gene complex for the aerosol delivery of a gene. The biopolymer/gene complex comprises a polyethyleneimine (PEI) having a substitution of glucose for at least a portion of the primary amino groups of the polyethyleneimine, and the content of the polyethyleneimine is 2-4 times the content of... Agent: Thelen Reid Brown Raysman & Steiner LLP

20070231272 - Process for preparing inhalable powders: The invention relates to a new process for producing powdered preparations for inhalation comprising a substance having a smaller particle size distribution and a substance having a larger particle size distribution, wherein a substance having a smaller particle size distribution and a substance having a larger particle size distribution are... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070231273 - Method for decreasing blood glucose levels: A method for decreasing blood glucose levels is disclosed. Iptakalim hydrochloride (a SUR1 subunit-dependent KATP channel blocker and a SUR2 subunit-selective KATP channel opener) is used to block pancreatic β-cell KATP channels, which depolarizes β-cells, elevates intracellular Ca2+ concentrations, and in turn increases insulin release. Therefore, in some implementations, iptakalim... Agent: Booth Udall, PLC

20070231275 - Method for regenerating tooth germ: It is an object of the present invention to provide a method for regenerating tooth germ, and more specifically, to provide a method for regenerating tooth germ with a size sufficient for enabling the treatment of patients who have lost teeth or have had teeth damaged by dental diseases such... Agent: Antonelli, Terry, Stout & Kraus, LLP

20070231280 - Ternary metal mixed oxide powder: Ternary, pyrogenically prepared, crystalline metal mixed oxide powder having the components titanium and silicon and a third component chosen from the group comprising aluminium, zirconium, zinc, tin, magnesium, yttrium, vanadium, tungsten, tantalum, cerium or boron. It is prepared by a procedure in which a vaporizable or atomizable silicon and titanium... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070231281 - Nail enamel compositions having a decorative color effect: A base coat nail enamel composition that forms a decorative color effect over natural or synthetic nails. The base coat nail enamel composition includes at least one dye in a sufficient amount, such that when a clear, tinted or pigmented top coat nail enamel composition is formed thereon, the combined... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070231284 - Alpha-msh-antagonist dipeptide conjugates: The invention relates to a dipeptide conjugate having general formula I, AA2-AA1-NH2, wherein A represent the radical corresponding to a monocarboxylic acid with general formula II, HOOC—R, in which: R represents a linear or branched aliphatic radical at C1-C24, which is optionally substituted by a hydroxyl group and which can... Agent: Foley And Lardner LLP Suite 500

20070231285 - Method for regulating the appearance of skin containing combination of skin care actives: A method for regulating the appearance of skin comprising topically applying to said skin a composition comprising: (a) a cosmetically or pharmaceutically acceptable carrier and about 0.05% to about 5% of an extract comprising a low molecular weight hydrolysable tannins, and mixtures thereof; (b) an effective amount of at least... Agent: Millen, White, Zelano & Branigan, P.C.

20070231283 - Process for bleaching keratin fibers: wherein R1 is a hydrogen, R2 is hydrogen, a substituted or unsubstituted C1- to C12-alkyl group, a substituted or unsubstituted C1- to C12-monohydroxy-alkyl group, a substituted or unsubstituted C2- to C12-polyhydroxy alkyl group, or a substituted saturated, unsaturated or aromatic 4- to 8-membered carbocycle or heterocycle, and R3 is a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070231282 - Skin lightening agents, compositions and methods: e

20070231286 - Color cosmetic compositions: Color cosmetic compositions include a rheology modifier (thickener) and film-former copolymer which is a crosslinked, linear copolymer of poly(vinyl amide polymerizable carboxylic acid) e.g. poly(vinyl pyrrolidone-acrylic acid), which is compatible with iron oxides generally present in such compositions, e.g. gel and emulsion color cosmetic formulations such as gel eyelid enhancers,... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070231287 - Cosmetic composition for care and/or treatment and/or makeup of the emulsion type structured with silicone polymers: Cosmetic emulsion for care and/or makeup, comprising an aqueous phase and a liquid fatty phase dispersed one within the other, said liquid fatty phase comprising at least one silicone oil and being structured with at least one gelling polymer (homopolymer or copolymer) with a weight-average molecular mass ranging from 500... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070231288 - Cosmetic use of d-ribose and method thereof: The invention relates to the use of D-ribose, in a cosmetic composition intended to optimize the metabolism of skin cells, to alleviate or to prevent the appearance of wrinkles and fine lines, to allow skin elasticity to be improved and to allow the freshness of the skin to be improved... Agent: Marsh, Fischmann & Breyfogle LLP

20070231289 - Use of ester quats in compositions as sand-repellent substances: The use of ester quats in compositions, the ester quats producing a sand-repellent action for the compositions, comprising cosmetic compositions, and the use of these cosmetic compositions having a sand-repellent action for topical application, for example for protection of the skin against ultraviolet radiation are provided. The present application in... Agent: Scully Scott Murphy & Presser, PC

20070231290 - Aerosol composition: A single phase aerosol composition comprising the following constituents: (a) 5 to 75 wt % of a hydrofluorocarbon(s) (HFC) of vapour pressure greater than or equal to 4 bar at 20° C. (60 psig at 70° F.); (b) 10 to 30 wt % of a hydrocarbon propellant; (c) 1 to... Agent: Norris, Mclaughlin & Marcus

20070231292 - Methods and systems for leaching silicone hydrogel ophthalmic lenses: This invention includes methods and systems for processing hydrogel lenses using aqueous solutions as leaching aids.... Agent: Philip S. Johnson Johnson & Johnson

20070231293 - Methods and systems for releasing silicone hydrogel ophthalmic lenses using surfactants: This invention includes methods and systems for processing hydrogel lenses using aqueous solutions as release aids.... Agent: Philip S. Johnson Johnson & Johnson

20070231294 - Ophthalmic compositions containing a synergistic combination of three polymers: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.... Agent: Alcon

20070231295 - Antimicrobial silicon oxide flakes: The present invention relates to SiOz flakes, especially porous SiOz flakes, wherein 0.70≦z≦2.0, especially 0.95≦z≦2.0, comprising an organic, or inorganic antimicrobial compound, or composition, which provide enhanced (long term) antimicrobial efficacy.... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070231291 - Polymeric anti-microbial agents: Polymeric anti-microbial agents produced by substituting the nitrogen atoms in the backbone of ethylenimine polymers are provided. The agents are believed to have low human toxicity while being effective against a variety of pathogens and are useful in applications involving human contact, such as cosmetics, hair care products and textiles,... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070231296 - Method of combating fruit flies: The present invention pertains to a method of combating fruit flies by bringing into contact the male and the female species with fipronil characterized in that a) the male species are lured onto a material containing a pheromone or a parapheromone and fipronil b) the male species take up fipronil... Agent: Hutchison Law Group PLLC

20070231298 - Cytokine-expressing cancer immunotherapy combinations: The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the sequential administration of the combination of a cytokine-expressing cancer immunotherapy composition and at least one tyrosine kinase inhibitor, wherein administration of the combination results in enhanced therapeutic... Agent: Dla Piper US LLP

20070231299 - Use of a promoter of t-cell expansion and an inducer of cd40 stimulation in the treatment or prevention of a pathologic state: The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer... Agent: Leydig, Voit & Mayer, Ltd.

20070231302 - Multipotent neural stem cells: An isolated multipotent neural stem cells has a phenotype identified by expression of the protein β-tubulin IV and Olig2 and the absence of the proteins NG2, PLP, and GFAP.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20070231303 - Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses: A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which... Agent: Howson And Howson

20070231304 - Prognostic factors for anti-hyperproliferative disease gene therapy: The present invention relates to the identification of various prognostic factors that predict response in patients with hyperproliferative disease such as cancer to gene therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy. Also described are methods of treatment for Li Fraumeni syndrome,... Agent: Fulbright & Jaworski L.L.P.

20070231309 - Cell populations which co-express cd49c and cd90: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070231308 - Glucagon-like-peptide-2 (glp-2) analogues: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g. as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16,... Agent: Clark & Elbing LLP

20070231310 - Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells: A method of preserving cone cells in the eye of a mammal suffering from a retinal degenerative disease comprises isolating from the bone marrow of the mammal a lineage negative hematopoietic stem cell population that includes endothelial progenitor cells, transfecting cells from the stem cell population with a gene that... Agent: Olson & Hierl, Ltd.

20070231311 - Method for preserving grain by-products: The present invention relates to an improved method for preserving grain by-products, aka “co-products,” such as wetcake, mash, silage, brewers' cake, and fine distiller's solubles (“syrup”), generated in the production of ethanol products and industrial grade ethanol (“ethanol process”), comprising treating these materials with an effective amount of probiotics, or... Agent: Michael J. Femal Femal & Associates

20070231306 - Isolated myeloid-like cell populations and methods of treatment therewith: The present invention provides an isolated myeloid-like cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen, CD11b antigen, and hypoxia inducible factor 1α (HIF-1α). These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly... Agent: Olson & Hierl, Ltd.

20070231314 - Polypeptides and compositions derived from the horny layer of the epidermis and its use: The present invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, a purified natural or synthetic epidermis-specific polypeptide which is involved in horny layer cell cohesion. The invention also relates to a cosmetic or pharmaceutical composition comprising a mixture of polypeptides derived from the proteolysis... Agent: Buchanan, Ingersoll & Rooney LLP

20070231315 - Stabilized preparations of serine endopeptidases, their preparation and use: The invention relates to stabilized preparations of serine endopeptidases which are suitable for use as a test reagent in a diagnostic procedure or for a therapeutic use. As a result of the addition of various additives, the preparations have improved stability and shelf life.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070231318 - Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases: The present invention relates to novel benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.... Agent: Dann, Dorfman, Herrell & Skillman

20070231317 - S100 protein inhibitors for treating leukemia: The present invention is directed to compounds, composition and method for reducing or inhibiting the differentiation or development of progenitor blood cells into leukemia cells, Particularly, the invention describes the use of inhibitors of S100 proteins, including myeloid related proteins (MRP). Inhibition of the activity or synthesis of S100 proteins... Agent: Birch Stewart Kolasch & Birch

20070231316 - Treatment of cognitive dysfunction in lupus: Methods of preventing binding of an anti-double stranded (ds)-DNA antibody to a neuron in a mammal exhibiting or at risk for lupus-induced cognitive dysfunction are provided. Methods of inhibiting progression of cognitive dysfunction in a mammal exhibiting or at risk for lupus-induced cognitive dysfunction are also provided. Also provided are... Agent: Amster, Rothstein & Ebenstein LLP

20070231319 - Methods of treating inflammatory and autoimmune diseases with natalizumab: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070231323 - Compositions and methods for the diagnosis and treatment of tumors of glial origin: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumors of glial origin in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070231322 - Compositions and methods for treating proliferative disorders such as nk-type ldgl: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative disorders such as NK-type LDGL, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to receptors present on the surface of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070231321 - Diabody which specifically binds streptococcus surface antigen i/ii and methods of use thereof: Common oral diseases such as periodontitis and dental caries can be prevented effectively by passive immunization. The present invention provides human single chain Fv (scFv) and diabody antibody fragments based on the binding characteristics of the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivatives bind specifically to... Agent: Licata & Tyrrell P.C.

20070231320 - Eggs having increased antibody titer and methods for making same: A method for increasing antigen-specific antibody titer in an egg by administering a cyclooxygenase inhibitor to an egg-laying animal prior to exposure to the antigen.... Agent: Quarles & Brady LLP

20070231326 - Immunological methods of treating cancer: A drug, affecting the hyperactivated immunologic effector cells, comprising (I) a Ca-antagonist and (II) an agent, reducing the intracellular cAMP/cGMP-ratio, is being described. In addition, a drug, affecting the hyperactivated immunologic effector cells, consisting of (I) an agent, eliminating the hyperactivated effector cells and (II) alloreactive cells with predetermined cell... Agent: Needle & Rosenberg, P.C.

20070231324 - Methods of using death receptor ligands and cd20 antibodies: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies... Agent: Genentech, Inc.

20070231325 - Prospective identification and characterization of breast cancer stem cells: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to... Agent: Medlen & Carroll, LLP Suite 350

20070231327 - Anti-ccr5 antibodies: This invention provides a monoclonal antibody or a fragment of such antibody, wherein the antibody or the fragment of such antibody binds to the same epitope as monoclonal antibody PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB12610). This invention also provides a hybridoma cell line... Agent: Cooper & Dunham LLP

20070231329 - Fc variants having increased affinity for fcyriib: The present invention relates to Fc variants having increased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070231328 - Method of treatment using humanized anti-cd11a antibodies: Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of... Agent: Genentech, Inc.

20070231330 - Method for the improvement of neuronal regeneration: A method for the improvement of neuronal regeneration by prevention or inhibition of basal membrane formation induced by a lesion of neuronal tissue.... Agent: Jacobson Holman PLLC

20070231331 - Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.... Agent: Buchanan, Ingersoll & Rooney LLP

20070231332 - Inhibition of cancer metastasis: P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors... Agent: Williams & Anderson PLC

20070231333 - Anti-5t4 antibodies and uses thereof: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070231334 - Combination therapy for anthrax using antibiotics and protease inhibitors: The invention provides compositions for treatment anthrax infection. The composition comprises a therapeutically effective amount of at least one B. anthracis metalloprotease inhibitor. The composition may further include an antimicrobial agent. The invention also provides methods for treating anthrax infection in a human or an animal subject. The method comprises... Agent: Hogan & Hartson L.L.P.

20070231335 - Compositions and methods for treating gram positive bacterial infection in a mammalian subject: Compositions and methods are provided for treating Gram positive bacterial infection in a mammalian subject. Compositions and methods are further provided for treating Gram positive bacterial skin infection in the mammalian subject. Compositions and methods are provided that comprise administering to the mammalian subject an effective amount of a compound... Agent: Woodcock Washburn LLP

20070231336 - Immunization against clostridium difficile disease: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of... Agent: Clark & Elbing LLP

20070231337 - Therapeutic and diagnostic anti-hsp 70 antibodies: Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue... Agent: J Mitchell Jones Medlen & Carroll`suite 350

20070231339 - Fungal immunostimulatory compositions: Methods are disclosed which are useful in increasing maturation of dendritic cells from CD14+ mononuclear cells, by contact with a composition comprising a fucose-containing glycoprotein fraction from Ganoderma lucidum. The extract can also be used for increasing production of a cytokine or a chemokine in a dendritic cell or CD19+... Agent: Greenberg Traurig LLP (la)

20070231340 - Multivalent pneumococcal polysaccharide-protein conjugate composition: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic... Agent: Alston & Bird LLP

20070231338 - Production and use of the methotrexate-albumin conjugate as an immunosuppressive agent in gvhd: The present invention relates to the use of active substance-protein conjugates for modulating and, in particular, for preventing transplantation-associated immune responses. In addition, the invention relates to novel, advantageous processes for preparing the conjugates which can be employed according to the invention.... Agent: Morris Manning Martin LLP

20070231341 - Cat dander allergen treatments: The present invention provides a method of reducing the major allergen in cat dander, Fel d1, and of reducing allergic response in mammals, including humans, sensitive to cat dander. Specifically to humans sensitive to the Fel d1 allergen that is shed by a cat. The treatment is achieved through administering... Agent: Pharmacia & Upjohn

20070231342 - Combination neisserial compositions: Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae... Agent: Novartis Vaccines And Diagnostics Inc.

20070231343 - Use of streptococcus suis 38 kda polypeptide as an immunogen: Disclosed are methods, compositions, and kits for inducing polyclonal antibodies against one or more pathogens that include Streptococcus suis. The methods may include administering to an animal a composition that includes an isolated 38 kDa polypeptide of Streptococcus suis and a suitable excipient. The methods, compositions, and kits may be... Agent: Foley & Lardner LLP

20070231344 - Conjugate vaccines for non-proteinaceous antigens: The present invention is directed to pharmaceutical compositions that can be used to immunize subjects using, for example, lipid, glycan, or nucleic acid antigens. These antigens are conjugated to a glycosphingolipid.... Agent: Wolf Greenfield & Sacks, P.C.

20070231345 - Medicament containing natural leucotriene inhibitors singly or in combination with bioavailable organic selenium supplement for hyperproliferative dermatological conditions and therapeutic methods thereof: The current invention discloses a medicament and its use in a method for therapeutically managing hyperproliferative diseases of the skin in particular, psoriasis of the skin, scalp and nails. The medicament includes a dual inhibitor of 5-lipoxygenase and human leukocyte elastase singly or in combination with a bioavailable organic selenium... Agent: Sabinsa Corporation

20070231346 - Apparatus and methods for vaccine development using ultrasound technology: Method and device for the creation of vaccines using ultrasonic waves, comprised of an ultrasound generator and a transducer to produce ultrasonic waves, is disclosed. The transducer has a specific ultrasound tip depending upon the type of delivery method utilized and depending on the shape of the vial containing the... Agent: Eilaz Babaev

20070231347 - Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost: An immunization regimen is provided which involves priming with an E1, E4-deleted adenovirus and boosting with an E1-deleted adenovirus. The second administered adenovirus has a capsid of a serotype which is not cross-reactive with the previously administered adenovirus. Each of the adenoviruses carries a heterologous expression cassette comprising a nucleic... Agent: Howson And Howson

20070231348 - High titer recombinant influenza viruses for vaccines: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes at least five internal genes from an influenza virus isolate that replicates to high titers in embryonated chicken eggs or MDCK cells.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070231349 - West nile vaccine: The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method... Agent: Wyeth Patent Law Group

20070231350 - West nile vaccine: The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method... Agent: Wyeth Patent Law Group

20070231351 - Cancer vaccine: The present invention relates to a method for producing a composition for use as a vaccine for treatment or prevention of cancer. The method includes the steps of isolating dendritic cells from a blood, bone marrow or other tissue sample of a patient suffering from cancer or from an unrelated... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070231353 - Compositons and methods for maintaining eyelid hygiene: The present invention is directed to novel compositions and methods effective for maintaining eyelid hygiene, e.g., therapeutic treatment and prophylaxis. The present invention further provides cleanser compositions and methods that are compliance-enhancing and useful for daily prophylaxis involving the easy and safe application directly to the eyelid in controlled doses... Agent: Edwards Angell Palmer & Dodge LLP

20070231352 - Mucoadhesive thermoresponsive medicament-carrier composition: This invention relates to a medicament-carrier composition for use in delivering medicaments or fixing the action site of biological active compounds, which mainly comprises a mucoadhesive polymer and a thermoresponsive polymer. The medicament-carrier composition according to this invention is quite suitable for use in topically delivering biological active compounds, especially... Agent: Bacon & Thomas, PLLC

20070231355 - Cosmetic composition comprising multiphasic particles: The present invention relates to multiphasic particles (MPPs), their design, composition, and use. The present invention also relates to products, and in particular, cosmetics, personal care products, and topical or dermatological products, which may be produced using MPPs.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070231356 - Thin film strips: A method of forming a thin film strip and thin film strips formed thereby where the method comprises coating a liner substrate with a wet slurry of film forming ingredients and other components and drying the wet slurry in a drying apparatus to form a film, measuring the moisture content... Agent: Perman & Green

20070231354 - Water-soluble thickener and cosmetic preparation containing same: The invention is a water-soluble thickener made of a copolymer that is obtained by copolymerizing 2-acrylamido-2-methylpropanesulfonic acid or its salt, hydroxyethylacrylamide, and a crosslinking monomer, or that is made of a copolymer that is obtained by further neutralizing said copolymer that has been obtained using an alkaline agent. It also... Agent: Townsend & Banta C/o Portfolio Ip

20070231357 - Insect repellent compound: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, which also has fragrance properties,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070231358 - Intravaginal treatment of vaginal infections with metronidazole compositions: The present invention provides a buffered non-flowing composition suitable for the treatment of bacterial vaginosis. The composition includes metronidazole in a concentration of about 0.50% (w/w) to about 1.50% (w/w). The metronidazole is present together with a buffer system in a physiologically tolerable medium. The buffer system provides an acidic... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070231360 - Neural conduit agent dissemination: A method for dissemination of a biocompatible agent using a neural conduit. In one embodiment, agent dissemination is facilitated, for example, by the application of thermal energy, ultrasound energy, radiant energy, electromagnetic energy, or electrical current. As one example, agent may be provided to a sensory organ such as the... Agent: Wood, Herron & Evans, LLP

20070231359 - Methods and compositions for piercing studs with bioactive polymer coating: Devices and methods for developing piercing instruments and studs that have bioactive polymer coating to promote healing, to minimize post-piercing infection, and to reduce inflammation are disclosed.... Agent: Daniel Murauski

20070231363 - Coatings formed from stimulus-sensitive material: A coating comprising a stimulus-responsive material and a bioactive agent for controlled release of the bioactive agent and methods of making and using the same are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20070231362 - Schistose microfibrillated article for cell growth: The present invention relates to culturing cells utilizing a matrix of microfibrillated thermoplastic polymeric materials. More specifically, the present invention relates to a method of culturing cells. In addition, the invention relates to a microfibrillated article for culturing cells dispersed in a cell culture medium. The matrix of thermoplastic polymeric... Agent: 3m Innovative Properties Company

20070231361 - Use of fatty acids to inhibit the growth of aneurysms: Methods of treating an aneurysm in a patient in need thereof are provided. The methods comprise delivering to a treatment site an effective amount of a fatty acid inhibitor of a matrix metalloproteinase (MMP) such that the fatty acid inhibitor of the MMP causes the regression of a pre-existing aneurysm.... Agent: Medtronic Vascular, Inc.IPLegal Department

20070231364 - Biocompatible membrane and process for producing the same: The present invention provides a biocompatible membrane which has a configuration that conforms well to an affected part and can be used in fields such as dentistry, oral surgery, orthopedics, etc., by a compatible membrane production process in which a biocompatible material is subjected to a lamination forming process or... Agent: Fitch, Even, Tabin & Flannery

20070231366 - Superabsorbent, freeze dried hydrogels for medical applications: Methods are provided for making freeze dried hydrogel and structures therefrom that may be introduced into a patient's body for medical applications. Precursor components are combined to initiate crosslinking. The combined precursor components are placed in a chilled tray, and allowed to crosslink to a desired level of complete crosslinking... Agent: Dardi & Associates, PLLC

20070231365 - Degradable polymeric implantable medical devices with a continuous phase and discrete phase: The invention provides an implantable medical device comprising: a structural element, wherein the structural element includes: a continuous phase comprising a first polymer; a discrete phase within the continuous phase, wherein the discrete phase has a second polymer including discrete phase segments; and anchor segments that have substantially the same... Agent: Squire, Sanders & Dempsey LLP

20070231367 - Bitterness-masking particulate jelly beverage: A particulate jelly beverage which facilitates the intake of a bitter drug and/or supplement. The beverage comprises 0.1 to 15.0% bitterness-masking ingredient comprising a vegetable fat or animal fat, 5 to 20% bitterness-masking aid comprising a sugar alcohol, 0.1 to 5.0% gellant such as an agar or carrageenan, and water... Agent: Knobbe Martens Olson & Bear LLP

20070231368 - Pharmaceutical formulations of 6-11 bicyclic macrolide derivative known as edp-182 and methods for preparation thereof: p

20070231370 - Guanidino acetic acid used as an animal food additive: The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in... Agent: Fulbright & Jaworski, LLP

20070231371 - Nutritional system and methods for increasing longevity: Disclosed herein are dietary formulations and methods to mimic the physiological, biochemical and gene expression effects of calorie restriction without altering dietary intake. The formulations include combinations of nutrients that have various intended functions in the body, falling into three or more of the following activities; (1) antioxidant activity; (2)... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070231369 - Ruminant feed composition and method of making: A nutrient or medicinal composition for administration to ruminants, which includes a core of one or more biologically active substances coated with a film of polyurethane, overcoated with an “intermediate” wax is disclosed. This polyurethane/wax coating is resistant to rumen conditions, but will release the biologically active substance(s) in the... Agent: Breiner & Breiner, L.L.C.

20070231372 - Tissue sealant: The present invention relates to a tissue sealant which is safe and effective. In accordance with the present invention, a tissue sealant comprising as an effective ingredient thrombin and fibrinogen characterized in that a bioabsorbable synthetic nonwoven fabric is used as a supporting material; use of a combination of a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070231373 - Transdermal steriod for formulation: Compounds of formula (I) (in which R1; R2, R3 and R4 are the same as or different from each other and each represents an oxo group, a hydroxy group, a mercapto group, a hydrogen atom, a halogen atom, an alkoxy group or an aryloxy group; and the dotted line indicates... Agent: Greenlee Winner And Sullivan P C

20070231377 - Compositions for promoting hair growth: The present invention provides compositions and methods for treating hair loss, nail brittleness and skin conditions, and for promoting or enhancing hair growth. The composition generally includes at least one methionine analog or derivative. The invention further provides structured fluid delivery systems comprising the compositions of the invention.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070231375 - Liposome combination and the use thereof: The present invention relates to a liposome combination, which wrapped hydrophilic drugs in water layer and wrapped hydrophobic drugs in lipid bilayer; hydrophobic drugs are photosensitizers. Using light with appropriate wavelength to activate the photosensitizer in the hydrophobic layer can result in the production of singlet oxygen and the free... Agent: Birch Stewart Kolasch & Birch

20070231374 - Composition comprising ether lipid: The invention provides a composition suitable for administration to a mammalian, particularly human, subject wherein the composition comprises an active agent and an amphilic component (containing at least one amphiphile) wherein at least a portion of the amphiphilic component is an ether-linked lipid and wherein the composition includes a non-lamellar... Agent: Nixon & Vanderhye, PC

20070231379 - Liposome-entrapped topoisomerase inhibitors: A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized... Agent: Philip S. Johnson Johnson & Johnson

20070231376 - Methods and compositions for modulating axonal outgrowth of central nervous system neurons: Methods and compositions for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic Brain Injury, cerebral aneurism, spinal cord injury and the like) and methods for inhibiting the axonal outgrowth of... Agent: David S. Resnick Nixon Peabody LLP

20070231378 - Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof: A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex;... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070231380 - Diagnosis and prognosis of wound infection by measurement of a phospholipase a2 in wound fluid: The present invention relates to the diagnosis, prognosis and/or treatment of wound infection by testing wound fluid for the presence of a marker which is present in an amount which is indicative of infection. The marker may be high molecular weight phospholipase A2 (cPLA2) or a marker which is correlated... Agent: Philip S. Johnson, Esq. Johnson & Johnson

20070231381 - Controlled-release dosage forms comprising zolpidem or a salt thereof: Controlled-release zolpidem compositions comprising granules that comprise zolpidem or a salt thereof, a water-insoluble polymer, and an enteric polymer.... Agent: Nixon & Vanderhye, PC

20070231382 - Pharmaceutical composition: Disclosed herein are tablets and methods of treatment comprising the administration of such tablets. The tablets are immediate release tablets that comprise about 400 mg of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, where the 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof comprises between 60 and 70% by... Agent: Novartis Corporate Intellectual Property

20070231384 - Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions: Methods are disclosed for forming a solid pharmaceutical composition having a desired release profile that include selecting hydroxypropylmethyl cellulose having a particular particle distribution to obtain the desired release profile, and forming a solid pharmaceutical composition comprising a core that comprises a bio-active and the hydroxypropylmethyl cellulose. Solid pharmaceutical compositions... Agent: Myers Bigel Sibley & Sajovec

20070231383 - Time-release compositions for delivery of [cr3o(carboxylate)6(h2o)3]+: t

20070231385 - Controlled release pharmaceutical composition and a process for preparing the same: A three-drug antiretrovial pharmaceutical composition having a selective combination of a controlled release active formulation and an immediate release active formulation for once daily administration. The composition provides desired dosages of the actives lamivudine, zidovudine or pharmaceutically acceptable derivatives thereof, and the immediate release formulation including at least one selective... Agent: Volpe And Koenig, P.C.

20070231386 - Novel pharmaceutical formulation containing a biguanide and an agiotension antagonist: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.... Agent: Hedman & Costigan P.C.

20070231389 - Non-homogenous dosage form coatings: The present invention is directed to liquid coating compositions and dosage forms having a continuous shell portion of a first composition and at least one discontinuous shell portion that is compositionally different located within the continuous shell portion. The present invention also provides a process for preparing a dosage form,... Agent: Philip S. Johnson Johnson & Johnson

20070231387 - Film-coated solid dosage forms: An orally dissolvable film coating for solid dosage forms which contains pullulan, one or more sensory cue agents, and a plasticizer. The film coating disintegrates in the mouth releasing the sensory cue agent resulting in an immediately perceivable sensory cue. A method for coating a solid oral dosage form with... Agent: Linda A. Vag Warner Lambert Company LLC

20070231388 - Novel pharmaceutical dosage form and manufacturing process: A manufacturing process for production of dosage forms for oral administration of active ingredients is described.... Agent: Nath & Associates PLLC

20070231390 - Formulations including hygroscopic compounds: The invention is directed to dosage forms suitable for the administration of hygroscopic active agents.... Agent: Davidson, Davidson & Kappel, LLC

20070231391 - Anti-microbial and hydrophilic article and methods for manufacturing the same: An antimicrobial and hydrophilic article that is microbial resistant comprises an antimicrobial agent and a hydrophilic agent combined with a base material. The combination can be extruded, calandarized, or molded to form the medical article, ensuring that the anti-microbial properties are not localized at the surface. The entire bulk of... Agent: Brian M. Burn, Esq. C.r. Bard Medical Division

20070231392 - Chemically modified polycation polymer for sirna delivery: The present invention provides a unique non-viral carrier for nucleic acid delivery in vitro and in vivo, and methods of using thereof.... Agent: Robert Deberardine Abbott Laboratories

20070231394 - Agent for removing circulatory dysfunction factor: An agent for removing a circulatory dysfunction factor, which is effective for ameliorating a circulatory dysfunction, particularly a heart failure, and for treating or preventing circulatory diseases, for example, heart diseases, such as a cardiac failure or a congestive cardiac failure, or a phlebemphraxis is provided. The agent for removing... Agent: Reed Smith LLP

20070231393 - System and device for magnetic drug targeting with magnetic drug carrier particles: Disclosed are methods of positioning a magnetic drug carrier particle within the body of a subject comprising placing an article within the body of the subject or external to the body of a subject; inserting a magnetic drug carrier particle into the body of the subject, and applying an external... Agent: Needle & Rosenberg, P.C.

20070231398 - Antisolvent emulsion solidification process: The invention relates to a process for the controlled production of particles comprising the steps of producing an emulsion comprising one or more compounds to be solidified in its dispersed phase, and dosing a suitable antisolvent to said emulsion, forcing the one or more compounds to solidify. Optionally, the solidified... Agent: Kenyon & Kenyon LLP

20070231396 - Medication spray formulation: Formulations for delivery of a pharmaceutical agent include a thixotropic agent. The pharmaceutical agent may be slowly released from a hydrogel or microcapsule in the spray formulation. Various formulations of reasonable thixotropic and hydrogel media are useful. Droplet size and thixotropy determine the distribution of the material along body surfaces... Agent: Dicke, Billig & Czaja

20070231397 - Method for producing coated drugs having a stable profile for the release of active ingredients: The invention relates to methods for producing drugs having a stable profile for the release of active ingredients, said drugs exhibiting a controlled release characteristic as a result of the coating of vinyl (co)polymers. The inventive methods are characterised in that the coated drugs are conditioned in a fluidised bed... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070231395 - Solid pharmaceutical preparation for dialysis: A solid pharmaceutical preparation for dialysis which does not contain any acetic acid and a production process thereof. The solid pharmaceutical preparation for dialysis contains two pharmaceutical preparations: a solid pharmaceutical preparation (A) composed of particles having an average particle size of about 100 μm to 1,500 μm and containing... Agent: Kubovcik & Kubovcik

20070231399 - Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms: Regarding an object of sufficient suppression of unpleasant taste in the oral cavity and quick dissolution in the gastrointestinal tract, which is generated when a drug having a strong unpleasant taste such as bitterness, astringency and the like is applied to a quickly disintegrating preparations in the oral cavity, this... Agent: Townsend And Townsend And Crew, LLP

20070231400 - Triggered release from proteinoid microspheres: The invention provides proteinoid microsphere made up of a mixture of thermally condensed amino acids that are crosslinked with a crosslinker reagent. The proteinoid microspheres of the invention may be used to encapsulate a material or a compound and to provide slow, sustained or timed release of the material or... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070231401 - Amniotic membrane preparations and purified compositions and anti-inflammation methods: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Wilson Sonsini Goodrich & Rosati

20070231402 - Therapeutic stem cell composition and stimulant, facilitator, accelerator, and synergizer thereof, growth factor, anti-inflammatory composition and uses thereof: The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering... Agent: Ip Group Of Dla Piper US LLP

20070231403 - Natural composite preservatives: Disclosed herein is a natural composite preservative comprising extracts from Camellia sinensis, Matricaria recutita, Citrus grandis, Magnolia biondii, propolis, Thujopsis dolabrata and Salix alba, in combination. The natural composite preservative has potent antibacterial activity against a wide spectrum of microorganisms in addition to being safe for the body, producing neither... Agent: O'keefe, Egan, Peterman & Enders LLP

20070231404 - Preparation derived from shark cartilage for treatment of diseases related to excessive phf or excessive intracellular calcium: Shark cartilage extract has been shown to be an antagonist of parathyroid hypertensive factor (PHF). In view of this, shark cartilage extract can be used to treat conditions related to excessive PHF activity. Such diseases include hypertension and some other diseases related to intracellular calcium elevation. Methods for producing the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070231405 - Compositions and methods using same for treating neurodegenerative disorders: Compositions and methods of using same are provided for the treatment of neurodegenerative disorders such as Glaucoma, Multiple Sclerosis, Myasthenia Gravis, Diabetic Neuropathy, Cerebrovascular accident, spinal cord injuries, ALS, Parkinson's disease and Idiopathic dementia.... Agent: Martin D. Moynihan Prtsi

20070231407 - Method of treating gallium-nitrate resistant tumors using gallium-containing compounds: The present invention relates to novel methods of using gallium containing compounds to treat mammals with gallium nitrate-resistant tumors.... Agent: Quarles & Brady LLP

20070231408 - Colloidal metal compositions and methods: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for... Agent: King & Spalding LLP

20070231406 - Use of gallium to treat biofilm-associated infections: The invention provides methods, compositions, and kits for treatment or prevention of biofilm-associated infections in an individual. Methods of the invention include administration of a gallium-containing composition for treatment of an established biofilm or prevention of formation of a biofilm. Some methods include administration of a gallium-containing composition in conjunction... Agent: Morrison & Foerster LLP

20070231409 - Drug and/or food supplement containing nisylen®, cepa, euphrasia, belladonna and/or mercurius solubilis: The present disclosure relates to a drug and/or food supplement with antiviral effects, in particular for the preventive and/or therapeutic treatment of herpes labialis and/or herpes genitalis, and/or with antibacterial and/or immunomodulating and/or antiphlogistic effects and/or for the preventive and/or therapeutic treatment of affections of the prostate, containing NISYLEN® and/or... Agent: Alleman Hall Mccoy Russell & Tuttle LLP

20070231410 - Disease modifying anti-arthritic activity of 2-methoxyestradiol: e

20070231411 - Method of inhibiting alveolar bone resorption and periodontal membrane loss and composition for internal use to be used therein: Alveolar bone resorption, periodontal membrane loss, and gingival recession can be inhibited by administering 500 mg to 2000 mg per day of calcium, 10 mg to 40 mg per day of soy isoflavone aglycone, and vitamin D3 to persons having a tendency for decreased bone density, postmenopausal women, and periodontal... Agent: Knobbe Martens Olson & Bear LLP

20070231412 - Virus-interacting layered phyllosilicates and methods of inactivating viruses in the gastrointestinal tract: Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses. Accordingly, provided herein is a method of inactivating a virus in the gastrointestinal tract of a mammalian subject comprising administering to said subject a composition comprising a layered phyllosilicate material in an amount effective for virus inactivation.... Agent: Marshall, Gerstein & Borun LLP

20070231413 - 1,3-benzodioxol compound and use of same: y

20070231414 - Composition having bone resorption inhibition-related effect and method for inhibiting bone resorption: The present invention has for its object to provide a method which comprises using edible and safe food components as active ingredients and promotes the OPG production promoting effect, RANKL expression inhibiting effect and osteoclast differentiation inhibiting effect, which take part in the prevention of bone resorption, and a composition... Agent: Connolly Bove Lodge & Hutz LLP

20070231415 - Compositions for safe and effective regression of spongiform pustule: Topical compositions for Safe and Effective regression of Spongiform Pustule in the form of ointment, cream, oil, soap and shampoo contain non aqueous herbal extract of Wrightia Tinctoria, cocos nucifera, and suitable pharmaceutically/cosmetically accepted excipients for dermal use.... Agent: Bregen Technical Consultants L.L.C.

20070231416 - Antiwrinkle agent and skin cosmetic composition: p

20070231418 - Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract: The invention provides a continuous process for obtaining triterpenes from plants and/or their components. The process can include continuously washing at least one of plant and plant parts in counter-current at 20° C. to 70° C. with a solvent in which the triterpenes are not soluble or only slightly soluble... Agent: Akerman Senterfitt

20070231417 - Use of guaiac wood for treating inflammation of the skin: One aspect of the present invention relates to the use of an extract from guaiac wood to produce a pharmaceutical composition for treating inflammations of the skin. Another aspect of the present invention relates to the use of an extract from guaiac wood as a cosmetic.... Agent: Morris Manning Martin LLP